Document:

EX-10.1

 Exhibit 10.1 
  

 
  

RESTRUCTURING SUPPORT AGREEMENT 

AMONG 
 MELINTA
THERAPEUTICS, INC. 
 AND 

THE SUPPORTING LENDERS IDENTIFIED HEREIN 

DATED AS OF DECEMBER 27, 2019 
  

 
  

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	ARTICLE I	  

	
	DEFINITIONS	  

			
	 Section 1.1
	 	Defined Terms	  	 	6	 
	 Section 1.2
	 	Terms Defined Elsewhere in this Agreement	  	 	16	 
	
	ARTICLE II	  

	
	DEFINITIVE DOCUMENTS	  

			
	 Section 2.1
	 	Incorporation of Exhibits and Schedules	  	 	18	 
	 Section 2.2
	 	Definitive Documents	  	 	18	 
	
	ARTICLE III	  

	
	COMMITMENTS OF THE SUPPORTING LENDERS	  

			
	 Section 3.1
	 	Support of Restructuring	  	 	18	 
	 Section 3.2
	 	Rights of Supporting Lenders Unaffected	  	 	20	 
	 Section 3.3
	 	Transfer of Claims	  	 	21	 
	
	ARTICLE IV	  

	
	COMMITMENTS OF THE COMPANY	  

	 Section 4.1
	 	Commitments of the Company	  	 	21	 
	 Section 4.2
	 	Rights of the Debtors Unaffected	  	 	24	 
	
	ARTICLE V	  

	
	REPRESENTATIONS AND WARRANTIES OF THE COMPANY	  

			
	 Section 5.1
	 	Qualification, Organization, Subsidiaries, etc.	  	 	25	 
	 Section 5.2
	 	Capitalization	  	 	26	 
	 Section 5.3
	 	Corporate Authority	  	 	26	 
	 Section 5.4
	 	Consents and Approvals	  	 	27	 
	 Section 5.5
	 	No Violations	  	 	27	 
	 Section 5.6
	 	SEC Filings; Financial Statements	  	 	28	 
	 Section 5.7
	 	No Undisclosed Liabilities	  	 	30	 
	 Section 5.8
	 	Absence of Certain Changes	  	 	30	 
	 Section 5.9
	 	Brokers or Finders	  	 	31	 
	 Section 5.10
	 	Litigation	  	 	31	 
	 Section 5.11
	 	Intellectual Property	  	 	31	 

  
 i 

							
	 Section 5.12
	 	Data Privacy and Cybersecurity; IT Assets	  	 	33	 
	 Section 5.13
	 	Real Property Leases	  	 	34	 
	 Section 5.14
	 	Material Contracts	  	 	34	 
	 Section 5.15
	 	Compliance with Laws; Anticorruption; Permits; Trade Compliance	  	 	37	 
	 Section 5.16
	 	Employee Benefit Matters	  	 	39	 
	 Section 5.17
	 	Labor Matters	  	 	40	 
	 Section 5.18
	 	Environmental Matters	  	 	41	 
	 Section 5.19
	 	FDA and Healthcare Regulatory Matters	  	 	41	 
	 Section 5.20
	 	Taxes	  	 	44	 
	 Section 5.21
	 	Insurance	  	 	46	 
	 Section 5.22
	 	No Other Representations; No Reliance	  	 	46	 
	
	ARTICLE VI	  

	
	REPRESENTATIONS AND WARRANTIES OF THE SUPPORTING LENDERS	  

			
	 Section 6.1
	 	Qualification; Organization	  	 	46	 
	 Section 6.2
	 	Corporate Authority	  	 	47	 
	 Section 6.3
	 	Consents and Approvals	  	 	47	 
	 Section 6.4
	 	No Violations	  	 	48	 
	 Section 6.5
	 	Brokers	  	 	48	 
	 Section 6.6
	 	Interested Stockholders	  	 	48	 
	 Section 6.7
	 	Ownership of Claims	  	 	48	 
	 Section 6.8
	 	No Other Representations; No Reliance	  	 	49	 
	
	ARTICLE VII	  

	
	COVENANTS	  

			
	 Section 7.1
	 	Interim Operations	  	 	49	 
	 Section 7.2
	 	Access and Information	  	 	52	 
	 Section 7.3
	 	Approvals and Consents; Cooperation; Notification	  	 	53	 
	 Section 7.4
	 	Employee Matters	  	 	54	 
	 Section 7.5
	 	Bidding Procedures	  	 	55	 
	
	ARTICLE VIII	  

	
	CONDITIONS PRECEDENT	  

			
	 Section 8.1
	 	Conditions to Obligation of the Company and the Supporting Lenders	  	 	56	 
	 Section 8.2
	 	Conditions to Obligation of the Company	  	 	56	 
	 Section 8.3
	 	Conditions to Obligation of the Supporting Lenders	  	 	57	 
	 Section 8.4
	 	Frustration of Conditions	  	 	58	 

  
 ii 

							
	ARTICLE IX	  

	
	TERMINATION	  

			
	 Section 9.1
	 	Termination	  	 	58	 
	 Section 9.2
	 	Termination Upon Effective Date or Outside Date	  	 	62	 
	 Section 9.3
	 	Effect of Termination	  	 	62	 
	
	ARTICLE X	  

	
	GENERAL PROVISIONS	  

			
	 Section 10.1
	 	Agreement Effective Time	  	 	62	 
	 Section 10.2
	 	No Solicitation	  	 	62	 
	 Section 10.3
	 	Purpose of Agreement	  	 	63	 
	 Section 10.4
	 	Admissibility of this Agreement	  	 	63	 
	 Section 10.5
	 	Several, Not Joint Obligations	  	 	63	 
	 Section 10.6
	 	Survival	  	 	63	 
	 Section 10.7
	 	Public Announcements	  	 	63	 
	 Section 10.8
	 	Notices	  	 	63	 
	 Section 10.9
	 	Descriptive Headings; Interpretative Provisions	  	 	65	 
	 Section 10.10
	 	Representation by Counsel; No Strict Construction	  	 	66	 
	 Section 10.11
	 	Entire Agreement	  	 	66	 
	 Section 10.12
	 	Governing Law and Venue; Waiver of Jury Trial	  	 	66	 
	 Section 10.13
	 	Transaction Expenses	  	 	67	 
	 Section 10.14
	 	Amendments and Waivers	  	 	67	 
	 Section 10.15
	 	Parties, Succession and Assignment	  	 	68	 
	 Section 10.16
	 	No Waiver of Participation and Reservation of Right	  	 	68	 
	 Section 10.17
	 	No Third-Party Beneficiaries	  	 	69	 
	 Section 10.18
	 	Counterparts; Effectiveness	  	 	69	 
	 Section 10.19
	 	Severability	  	 	69	 
	 Section 10.20
	 	Specific Performance	  	 	69	 
	 Section 10.21
	 	Conflicts	  	 	69	 

  

			
	Exhibit A	  	Restructuring Term Sheet
	Exhibit B	  	Interim Cash Collateral Order
	Exhibit C	  	Form of Transfer Joinder
	Exhibit D	  	First Day Pleadings
	Exhibit E	  	Bidding Procedures Order
	Exhibit F	  	Interfund Transfers

  
 iii 

  

THIS RESTRUCTURING SUPPORT AGREEMENT DOES NOT CONSTITUTE (NOR SHALL IT BE CONSTRUED AS) AN OFFER WITH RESPECT TO ANY SECURITIES OR A SOLICITATION OF
ACCEPTANCES OR REJECTIONS AS TO ANY PLAN OF REORGANIZATION, IT BEING UNDERSTOOD THAT SUCH A SOLICITATION, IF ANY, ONLY WILL BE MADE IN COMPLIANCE WITH APPLICABLE PROVISIONS OF SECURITIES, BANKRUPTCY, AND/OR OTHER APPLICABLE LAWS. 

 
  

RESTRUCTURING SUPPORT AGREEMENT 

This RESTRUCTURING SUPPORT AGREEMENT (together with all exhibits, schedules and attachments hereto, as amended, supplemented or otherwise
modified from time to time in accordance with the terms hereof (this “Agreement”)), dated as of December 27, 2019, is among Melinta Therapeutics, Inc., a Delaware corporation (“Melinta” or the
“Company”), on behalf of itself and its Subsidiaries listed on Annex A to the Restructuring Term Sheet (each, a “Company Subsidiary” and collectively, the “Company
Subsidiaries,” and, together with Melinta, each a “Debtor,” and collectively, the “Debtors”), Deerfield Private Design Fund III, L.P. (“PDIII”) and Deerfield Private Design Fund IV, L.P.
(“PDIV”, and together with PDIII, the “Supporting Lenders”), the lenders (after giving effect to the transfers described in Exhibit F) pursuant to that certain Facility Agreement, dated as of January 5,
2018 (as amended by that certain First Amendment to Facility Agreement, dated as of January 14, 2019, and as further amended, supplemented, or otherwise modified from time to time in accordance with the terms thereof, the “Prepetition
Credit Agreement”), by and among Melinta, Cortland Capital Markets, LLC, as agent (in such capacity, the “Prepetition Agent”), and the Supporting Lenders, as lenders (the “Prepetition Lenders”). The Company
and the Supporting Lenders are each referred to herein as a “Party” and collectively, the “Parties.” Capitalized terms used herein but not otherwise defined have the meanings ascribed to them in the Restructuring
Term Sheet. 
 RECITALS 

WHEREAS, the Debtors are engaged in the business of, directly or indirectly, researching, developing, making or having made, promoting,
marketing, using, licensing and selling the medicinal or pharmaceutical products, product candidates or therapies that are as of the date of this Agreement being researched, developed, tested (including through clinical trials), commercialized,
manufactured, stored, sold, licensed, or distributed by or on behalf of any of the Debtors, including (i) delafloxacin, known as Baxdela®, (ii) minocycline, known as Minocin® for injection, (iii) oritavancin, known as Orbactiv® and (iv) meropenem and vaborbactam, known as Vabomere® (such business, the “Business”; and Baxdela®, Minocin®, Orbactiv®, Vabomere®, in each case, including any Variant thereof, and any other pharmaceutical or other compounds, compositions, formulations,
methods, processes, materials, products, product candidates or therapies that have been acquired, or have been or are under development, manufacture, distribution or commercialization, by or on behalf of any of the Debtors (including any Affiliate
thereof), taken together, the “Products”); 
 WHEREAS, prior to the date of this Agreement, the Parties, Deerfield Special
Situations Fund, L.P. (“DSS”) and the Prepetition Agent were party to the Prepetition Credit Agreement; 

  
 4 

 WHEREAS, DSS has transferred its Prepetition Credit Agreement Claims to the Supporting
Lenders as set forth in Exhibit F; 
 WHEREAS, the Prepetition Agent holds first-priority (subject to certain Permitted Liens (as
defined in the Prepetition Credit Agreement)) liens on all Collateral (as defined in the Prepetition Security Agreement), which includes substantially all of the assets of the Debtors, including all Company Intellectual Property; 

WHEREAS, as of the date and time of this Agreement, the Company has not commenced a case under chapter 11 of Title 11 of the United
States Code (the “Bankruptcy Code”); 
 WHEREAS, the Parties have negotiated a restructuring of the Company (the
“Restructuring”) which shall be implemented in accordance with a pre-negotiated chapter 11 plan of reorganization (the “Plan”) that implements a reorganization and recapitalization of the Company pursuant to
chapter 11 cases (the “Chapter 11 Cases”) commenced under the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), subject to the
Debtors’ evaluation of Alternative Transactions in accordance with the terms hereof and in accordance with the Bidding Procedures (as defined herein); 

WHEREAS, subject to the Company’s evaluation of Alternative Transactions as set forth herein and in the Bidding Procedures, the
Restructuring contemplated by this Agreement shall be implemented upon the terms and conditions set forth in the term sheet attached hereto as Exhibit A (together with all exhibits, schedules, and attachments thereto and as
amended, supplemented, or otherwise modified from time to time in accordance with the terms hereof, the “Restructuring Term Sheet”); 

WHEREAS, subject to Bankruptcy Court approval, the Debtors have obtained the agreement for the consensual use of “cash collateral”
pursuant to the terms and conditions of the proposed interim cash collateral order attached hereto as Exhibit B (the “Interim Cash Collateral Order”) and a proposed final order to be on terms substantially
identical to the terms set forth in the Interim Cash Collateral Order with such changes necessary to convert the Interim Cash Collateral Order into a final order (the “Final Cash Collateral Order” and together with the Interim Cash
Collateral Order the “Cash Collateral Orders” and each a “Cash Collateral Order”) to be entered by the Bankruptcy Court in form and substance mutually acceptable to the Company and the Requisite Supporting Lenders;

 WHEREAS, in order to effectuate the Restructuring, the Debtors intend to file petitions commencing (the date of commencement being the
“Petition Date”) the Chapter 11 Cases under chapter 11 of the Bankruptcy Code; 
 WHEREAS, this Agreement is the
product of arm’s-length, good-faith negotiations among the Parties and is not intended to be and shall not be deemed to be a solicitation of acceptances of any chapter 11 plan; and 

  
 5 

 WHEREAS, the Parties have agreed to support the Restructuring subject to and in accordance
with the terms of this Agreement and to use commercially reasonable efforts to complete the negotiation of the terms of the documents and completion of the actions specified to effect the Restructuring in accordance with the Restructuring Term
Sheet. 
 NOW, THEREFORE, in consideration of the promises and mutual covenants and agreements herein contained and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties covenant and agree as follows: 

ARTICLE I 

DEFINITIONS 

Section 1.1 Defined Terms. As used in this Agreement, the following terms have the following meanings: 

“Affiliate” means, with respect to any Person, any other Person that, directly or indirectly, controls, is controlled by, or
is under common control with, such Person, and the term “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of such Person, whether through ownership of voting securities, by contract or otherwise. 

“Agreement” has the meaning set forth in the Preamble and shall include the Exhibits, Annexes and Schedules annexed hereto or
referred to herein. 
 “Antitrust Laws” means any applicable supranational, national, federal, state, county or local
antitrust, competition or trade regulation Laws that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade or lessening competition through merger or acquisition,
including the HSR Act, the Sherman Act, the Clayton Act and the Federal Trade Commission Act, in each case, as amended, and other similar antitrust, competition or trade regulation Laws of any jurisdiction other than the United States. 

“Approved KEIP” means that certain Key Employee Incentive Plan as consented to by the Supporting Lenders prior to the
Petition Date. 
 “Bidding Procedures” means the bidding procedures in the form attached to the Bidding Procedures Orders,
to be approved by the Bankruptcy Court in the Chapter 11 Cases (and which for the avoidance of doubt shall not be modified in any respect without the consent of the Requisite Supporting Lenders). 

“Bidding Procedures Order” means the order in the form attached hereto as Exhibit E, approving,
among other things, the Bidding Procedures, to be entered by the Bankruptcy Court in the Chapter 11 Cases (and which for the avoidance of doubt shall not be modified in any respect without the consent of the Requisite Supporting Lenders). 

  
 6 

 “Books and Records” means all documents of, or otherwise in the possession,
custody or control of, or used by, the Debtors in connection with, or relating to, the Business or the operations of the Debtors, including all books and records (financial, laboratory and otherwise), files, instruments, papers, microfilms,
photographs, letters, budgets, forecasts, ledgers, journals, title policies, lists of past, present and/or prospective customers, supplier lists, regulatory filings, billing records, and patient support and market research programs and related
databases, documents relating to the filing, prosecution, maintenance, enforcement or defense of Intellectual Property, technical documentation (design specifications, functional requirements, operating instructions, logic manuals, flow charts,
etc.), user documentation (installation guides, user manuals, training materials, release notes, working papers, etc.), data (including safety data, clinical trial data, patient data), reports (including environmental reports and assessments),
plans, mailing lists, price lists, marketing information and procedures, advertising and promotional materials, equipment records, warranty information, architects agreements, construction contracts, drawings, plans and specifications, records of
operations, standard forms of documents, and related books, records and workpapers, manuals of operations or business procedures and other similar procedures (including all discs, tapes and other media-storage data containing such information), all
complaint files and adverse event files in the safety and quality databases of the Debtors or their Affiliates, in each case, whether or not in electronic form. 

“Business Day” means any day other than Saturday, Sunday and any day that is a legal holiday or a day on which banking
institutions in New York, New York are authorized by Law or other governmental action to close. 
 “Business Permits” means
all Permits that are required for the operation of the Business, in each case, as conducted or owned and used by the Debtors on the date of this Agreement. 

“Cause of Action” means any action, suit, claim, complaint, litigation, investigation, proceeding, arbitration or other
similar dispute by or before any Governmental Entity. 
 “Claim” means any “claim” (as defined in
section 101(5) of the Bankruptcy Code) against the Debtors. 
 “Code” means the Internal Revenue Code of 1986, as
amended. 
 “Company Intellectual Property” means all Intellectual Property owned or purported to be owned by the Company
or any of its Subsidiaries, including all Owned Registered Intellectual Property, and all of the Company’s and each of its Subsidiaries’ rights therein, and, in the case of Trademarks, all goodwill associated with or symbolized thereby.

 “Company IT Assets” means the IT Assets owned, used or held for use by any of the Company or any of its Subsidiaries.

 “Company Specified Representations” means the representations and warranties contained in the first sentence of
Section 5.1, Section 5.3 and Section 5.9. 

“Confirmation Order” has the meaning set forth in the definition of “Definitive Documents.” 

“Contract” means any agreement, commitment, promise, undertaking, contract, subcontract, settlement agreement, lease,
sublease, instrument, permit, concession, franchise, binding understanding, note, option, bond, mortgage, indenture, trust document, loan or credit agreement, license, sublicense, insurance policy or other legally binding commitment or instrument,
whether written or oral. 

  
 7 

 “Copyrights” means all copyrights and applications for copyright. 

“Debtor Plan” means any benefit or compensation plan, program, policy, practice, agreement, contract, arrangement or other
obligation, whether or not in writing and whether or not funded, in each case, which is sponsored or maintained by, or required to be contributed to, or with respect to which any potential liability is borne by, any of the Debtors or any of their
Subsidiaries. Debtor Plans include, but are not limited to, “employee benefit plans” within the meaning of Section 3(3) of ERISA, whether or not subject to ERISA, employment, consulting, retirement, severance, separation, termination
or change in control agreements, relocation, repatriation, expatriation, termination pay, performance awards, bonuses, incentives, equity-based awards, phantom equity, supplemental retirement, deferred compensation, profit sharing, insurance,
medical, welfare, fringe or other benefits, but excluding any such plans established pursuant to statute. 
 “Deerfield”
means Deerfield Management Company, L.P. and its Affiliates. 
 “Definitive Documents” means (i) the Plan and Plan
Supplement (including all exhibits and supplements thereto); (ii) the disclosure statement with respect to such Plan (the “Disclosure Statement”), the other solicitation materials in respect of the Plan (such materials,
collectively, the “Solicitation Materials”), the motion to approve the Disclosure Statement and Solicitation Materials and the order to be entered by the Bankruptcy Court approving the Disclosure Statement and Solicitation Materials
as containing, among other things, “adequate information” as required by section 1125 of the Bankruptcy Code (the “Disclosure Statement Order”); (iii) the order to be entered by the Bankruptcy Court confirming the
Plan (the “Confirmation Order”) and pleadings in support of entry of the Confirmation Order; (iv) those motions and proposed court orders that the Company files on or after the Petition Date and seeks to have heard on an
expedited basis at the “first day hearing,” which shall consist of the motions and proposed orders listed on Exhibit D hereto; (v) the documents or agreements for the governance of the reorganized Company,
including any shareholders’ agreements and certificates of incorporation; (vi) the documents or agreements related to any management incentive plan or management or consulting agreements of the reorganized Company to the extent such plan
or agreements are part of the Plan or Plan Supplement; (vii) all agreements relating to warrants or other interests exercisable into shares of the reorganized Company; (viii) the Final Cash Collateral Order; and (ix) such other
documents, pleading, agreements or supplements as may be reasonably necessary or advisable to implement the Restructuring; and in the case of all such documents described in clauses (i) through (ix) consistent in all respects with the
Restructuring Term Sheet, and except as otherwise set forth in the Restructuring Term Sheet, reasonably acceptable in form and substance to the Requisite Supporting Lenders and the Debtors, and in the case of the Final Cash Collateral Order,
acceptable to the Requisite Supporting Lenders. 
 “Disclosure Statement” has the meaning set forth in the definition of
“Definitive Documents.” 

  
 8 

 “Disclosure Statement Order” has the meaning set forth in the definition of
“Definitive Documents.” 
 “Effective Date” means the date that the Plan becomes effective. 

“EMA” means the European Medicines Agency. 

“Encumbrance” means any lien, pledge, hypothecation, mortgage, deed of trust, security interest, encumbrance, covenant,
charge, claim, lease, sublease, option, right of first refusal, easement, servitude, restrictive covenant, encroachment, right of use or possession, right of way, encroachment, occupancy right, preemptive right, community property interest or
restriction of any nature, whether arising prior to or subsequent to the commencement of the Chapter 11 Cases, and whether imposed by Law, Contract or otherwise. 

“Environmental Laws” means all Laws relating to the protection of the environment. 

“Equity Interests” means all equity interests of any kind, including common and preferred stock, options, warrants and other
agreements or rights to acquire the same (including any arising under or in connection with any employment agreement, incentive plan, benefit plan, or the like). 

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated and rulings
issued thereunder. 
 “ERISA Affiliate” means, with respect to any entity, trade or business, any other entity, trade or
business that is a member of a group described in Section 414(b), (c), (m) or (o) of the Code or Section 4001(b)(1) of ERISA that includes the first entity, trade or business, or that is a member of the same “controlled
group” as the first entity, trade or business pursuant to Section 4001(a)(14) of ERISA. 
 “ERISA Plan” means an
“employee benefit plan” within the meaning of Section 3(3) of ERISA. 
 “Estates” means individually or
collectively, the estate or estates of each Debtor created under section 541 of the Bankruptcy Code. 
 “Exchange Act”
means the Securities Exchange Act of 1934, as amended. 
 “Excluded Matter” has the meaning set forth in the definition of
“Material Adverse Effect”. 
 “FDA” means the United States Food and Drug Administration. 

“FDCA” means the U.S. Food, Drug and Cosmetic Act of 1938, as amended (21 U.S.C. § 301 et seq.). 

  
 9 

 “Final Order” means an Order which has not been stayed (or with respect to
which any stay has been lifted) and (i) as to which the time to file an appeal, a motion for rehearing or reconsideration (excluding any motion under Section 60(b) of the Federal Rules of Civil Procedure) or a petition for writ of
certiorari has expired and no appeal, motion, stay or petition is pending, or (ii) in the event that such an appeal or petition thereof has been sought, either (A) such Order shall have been affirmed by the highest court to which such
Order was appealed or certiorari shall have been denied, and the time to take any further appeal or petition of certiorari shall have expired or (B) such appeal, motion, stay or petition shall not have been granted and shall no longer be
pending and the time for seeking such appeal, motion, stay or petition shall have expired. 
 “GAAP” means United States
generally accepted accounting principles. 
 “Good Clinical Practices” means, with respect to the Company and its
Subsidiaries, standards for clinical trials for pharmaceuticals (including all applicable requirements relating to protection of human subjects), as set forth in the FDCA, applicable regulations promulgated thereunder (including, for example, 21
C.F.R. Parts 50, 54, 56, and 312), and applicable guidance documents, as amended from time to time, and such standards of good clinical practice (including all applicable requirements relating to protection of human subjects) as are required by
Regulatory Authorities in any other countries in which the Products are sold or intended to be sold, including applicable regulations or guidelines from the International Conference on Harmonization of Technical Requirements for Registration of
Pharmaceuticals for Human Use, to the extent such standards are more stringent than those applicable in the United States. 
 “Good
Laboratory Practices” means, with respect to the Company and its Subsidiaries, standards for pharmaceutical laboratories, as set forth in the FDCA, applicable regulations promulgated thereunder (including, for example, 21 C.F.R. Part 58),
and applicable guidance documents, as amended from time to time, and such standards of good laboratory practices as are required by Regulatory Authorities in any other countries in which the Products are sold or intended to be sold, including
applicable regulations or guidelines from the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, to the extent such standards are more stringent than those applicable in the United
States. 
 “Good Manufacturing Practices” means, with respect to the Company and its Subsidiaries, standards for the
manufacture, processing, packaging, testing, transportation, handling and holding of drug products, as set forth in the FDCA, applicable regulations promulgated thereunder (including, for example, 21 C.F.R. Parts 210 and 211), and applicable
guidance documents, as amended from time to time, and such standards of good manufacturing practices as are required by Regulatory Authorities in any other countries in which the Products are sold or intended to be sold, including applicable
regulations or guidelines from the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, to the extent such standards are more stringent than those applicable in the United States.

 “Governmental Entity” means any U.S. or non-U.S. governmental or regulatory
authority, agency, commission, body, court or other legislative, executive, judicial, or administrative governmental entity at any level, or any agency, department or instrumentality thereof. 

  
 10 

 “Hazardous Substance” means any substance that is listed, classified or
regulated pursuant to any Environmental Law. 
 “Health Laws” means any Law of any Governmental Entity (including
multi-country organizations) the purpose of which is to ensure the safety, efficacy and quality of medicines or pharmaceuticals by regulating the research, development, manufacturing and distribution of these products, including Laws relating to
Good Laboratory Practices, Good Clinical Practices, investigational use, product marketing authorization, manufacturing facilities compliance and approval, Good Manufacturing Practices, labeling, advertising, promotional practices, safety
surveillance, recordkeeping and filing of required reports and their respective counterparts promulgated by Regulatory Authorities in countries outside the United States including (a) the FDCA (21 U.S.C. § 301 et seq.) and the regulations
and applicable guidance promulgated thereunder, (b) the Public Health Service Act (42 U.S.C. § 201 et seq.) and the regulations and applicable guidance promulgated thereunder, (c) all U.S. federal, state, and local healthcare related
fraud and abuse Laws, including the U.S. Federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), the civil False Claims Act (31 U.S.C. § 3729 et seq.), the administrative False Claims Law (42 U.S.C.
§ 1320a-7b(a)), the Anti-Inducement Law (42 U.S.C. § 1320a-7a(a)(5)), the exclusion Laws (42 U.S.C. §
1320a-7), all criminal laws relating to healthcare fraud and abuse, including 18 U.S.C. §§ 286 and 287, and the regulations promulgated pursuant to such statutes, (d) the Health Insurance
Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. § 17921 et seq.), the regulations promulgated thereunder and comparable
state Laws and (e) all comparable Laws administered by Regulatory Authorities outside of the United States, each of clauses (a) through (e) as may be amended from time to time. 

“HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 

“Incentive Compensation Plan” means the Melinta Therapeutics Inc. Sales Incentive Plan, effective October 1, 2019. 

“IND” means an Investigational New Drug Application submitted to the FDA pursuant to 21 C.F.R. Part 312 (as amended
from time to time) with respect to the Products, or the equivalent application or filing submitted to any equivalent Regulatory Authority outside the United States of America (including any supranational agency such as the EMA), and all supplements,
amendments, variations, extensions and renewals thereof that may be submitted with respect to the foregoing. 

“Indebtedness” means, with respect to any Person, (a) all obligations for borrowed money, (b) all obligations
evidenced by bonds, debentures, notes or similar instruments, (c) all Indebtedness of others secured by any Encumbrance on owned or acquired property of the reference Person, whether or not the Indebtedness secured thereby has been assumed,
(d) all guarantees (and any other arrangement having the economic effect of a guarantee) of Indebtedness of others, (e) all obligations, contingent or otherwise, of such Person as an account party in respect of financial guaranties,
letters of credit, letters of guaranty, surety bonds and other similar instruments, (f) all obligations representing the deferred and unpaid purchase price of property (other than trade payables incurred in the ordinary course of business
consistent with past practice), (g) all obligations, contingent or otherwise, in respect of bankers’ acceptances and (h) net cash payment obligations of such Person under swaps, options, derivatives and other hedging agreements or
arrangements that will be payable upon termination thereof (assuming they were terminated on the date of determination). 

  
 11 

 “Intellectual Property” means all intellectual property rights and
proprietary rights of any kind or nature, including any and all of the following arising in any jurisdiction of the world: (a) Patents; (b) Trademarks; (c) Trade Secrets; (d) Copyrights; (e) internet domain names; and (f) all
applications for, and registrations of, any of the foregoing. 
 “Inventory” means all raw materials, work-in-progress, finished goods, supplies (including clinical drug supplies), samples (including samples held by sales representatives), components, package inserts,
packaging and labeling materials, and other inventories to which the Debtors have title that are in the possession of the Debtors or any third party and used or held for use in connection with any Product or related to the Business, including
(i) all of the Products that are in a finally packaged form for distribution to end users with all legally required warnings, labeling and packaging and (ii) all active pharmaceutical ingredients. 

“IRS” means the Internal Revenue Service of the United States. 

“IT Assets” means technology devices, computers, Software, servers, networks, workstations, routers, hubs, circuits,
switches, data communications lines, and all other information technology equipment and all associated documentation. 

“Knowledge of the Debtors” means the actual knowledge of the individuals set forth on Section 1.1
of the Company Disclosure Letter. 
 “Law” means any U.S. or non-U.S. federal,
state, provincial or local law, statute, code, ordinance, rule, regulation, Order, stipulation, award or common law requirement. 

“Lender Specified Representations” means the representations and warranties contained in the first sentence of
Section 6.1, Section 6.2 and Section 6.5. 

“Liability” means any debt, loss, liability, claim (including “claim” as defined in the Bankruptcy Code),
commitment, undertaking, damage, expense, fine, penalty, cost, royalty or obligation (including those arising out of any action, such as any settlement or compromise thereof or judgment or award therein), of any nature, whether known or unknown,
disclosed or undisclosed, express or implied, primary or secondary, direct or indirect, matured or unmatured, fixed, absolute, contingent, accrued or unaccrued, asserted or not asserted, liquidated or unliquidated, and whether due or to become due,
and whether in Contract, tort or otherwise. 
 “Licensed IP” means any Intellectual Property that is licensed to, or
subject to a covenant not to sue for the benefit of, the Company or any of its Subsidiaries. 
 “Material Adverse Effect”
means any event, change, effect, condition, state of facts or occurrence (regardless of whether such event, change, effect, condition, state of facts or occurrence constitutes a breach of any representation, warranty or covenant of the Debtors
hereunder) which has had or would reasonably be expected to have, individually or when 

  
 12 

 
considered together with any other events, changes, effects, conditions, states of facts or occurrences, (a) a material adverse effect on or a material adverse change in or to the business,
results of operations, financial condition, assets, or liabilities of the Company and its Subsidiaries (taken as a whole) or (b) a material adverse effect on the ability of the Debtors to consummate the Transactions or perform their obligations
under this Agreement or the Restructuring Term Sheet on a timely basis; provided, however, that a Material Adverse Effect shall not be deemed to include events, changes, effects, conditions, states of facts or occurrences arising out
of, relating to or resulting from: (i) changes in the United States or foreign economies or financial markets in general, (ii) general changes or developments in business, regulatory or macroeconomic conditions or trends that affect the
industries and markets in which the Business operates, (iii) public announcement of this Agreement or the Chapter 11 Cases, the public announcement or the consummation of the Restructuring and the Transactions, the commencement of the
Chapter 11 Cases or the identity of the Supporting Lenders, (iv) any action or omission by the Supporting Lenders in breach of this Agreement, (v) any action which is expressly requested in writing by a Supporting Lender,
(vi) changes in any applicable Laws or applicable accounting regulations or principles or the enforcement or interpretation thereof, (vii) any outbreak or escalation of hostilities or war or any act of terrorism or natural disaster or act
of God and (viii) any failure of the Business to meet any budgets, plans, projections or forecasts (internal or otherwise) or any decline in the trading price or trading volume of the Company’s common stock or any change in the ratings or
ratings outlook for the Company as a result of the commencement of the Chapter 11 Cases (each of clauses (i) through (viii), an “Excluded Matter”); provided further that with respect to clauses (i), (ii), (vi) and
(vii), such effects shall not be deemed to arise out of, relate to or result from an Excluded Matter to the extent the same disproportionately adversely affects the Company and its Subsidiaries or the Business, in each case, taken as a whole, as
compared to other similarly situated entities or businesses. 
 “Milestones” means those Milestones set forth in
Annex D to the Restructuring Term Sheet. 
 “Nasdaq” means the Nasdaq Stock Exchange. 

“NDA” means a new drug application for a drug submitted to the FDA pursuant to 21 C.F.R. Part 314 (as amended from time to
time), and all amendments or supplements thereto, including all documents, data and other information concerning the applicable drug which are necessary for FDA approval to market such drug in the United States, and any equivalent application
submitted to any other Regulatory Authority outside of the United States, and all supplements, amendments, variations, extensions and renewals thereof that may be submitted with respect to the foregoing. 

“OFAC” means the Office of Foreign Asset Control of the United States Department of the Treasury. 

“Order” means any order, injunction, judgment, decree, ruling, writ, assessment or arbitration award of, or entered, issued,
made or rendered by, a Governmental Entity, or any settlement agreement entered in connection therewith. 
 “Outside Date”
means April 30, 2020 at 11:59 p.m. Eastern Time. 

  
 13 

 “Patents” means patents and patent applications, invention disclosures and
rights in respect of utility models or industrial designs, including all related continuations, continuations-in-part, divisionals, reissues, re-examinations, renewals, revisions, supplementary protection certificates, substitutions, and extensions thereof. 

“Permits” means all licenses, permits, franchises, approvals, registrations, listings, authorizations, consents or orders of,
or filings with, any Governmental Entity. 
 “Permitted Encumbrance” means any (a) Encumbrances for Taxes not yet due
and payable or that are being contested in good faith through appropriate proceedings, (b) Encumbrance for assessments and other governmental charges or landlords’, carriers’, warehousemen’s, mechanics’, repairmen’s,
workers’ or any similar Encumbrance incurred in the ordinary course of business consistent with past practice, in each case, for sums not yet due and payable or due, but not delinquent or being contested in good faith by appropriate
proceedings, (c) Encumbrance imposed or promulgated by applicable Law or any Governmental Entity with respect to real property, including zoning, building, fire, health and Environmental Laws and similar regulations, (d) pledges or
deposits in connection with workers’ compensation, unemployment insurance, social security and other similar legislation, (e) Encumbrance incurred in the ordinary course of business consistent with past practice, in connection with
workers’ compensation, unemployment insurance and other types of social security, (f) licenses, covenants not to sue or similar rights with respect to Intellectual Property that are granted in the ordinary course of business and
(e) those Encumbrances granted under the Cash Collateral Orders. 
 “Person” means any individual, partnership, joint
venture, limited liability company, corporation, trust, unincorporated organization, group, governmental or regulatory authority, or any other legal entity or association, including the United States Trustee and any official or ad hoc committee
formed in the Chapter 11 Cases. 
 “Personal Information” means any information or data that alone, or together with
any other data or information, identifies any person or device, and any other personal information whose processing, security, collection, storage, use, disclosure, transfer or other exploitation is governed under any applicable Laws with respect to
privacy or data protection. 
 “Plan Supplement” means the documents and forms of documents, schedules and exhibits to the
Plan, to be filed by the Debtors no later than ten (10) calendar days before the deadline to vote on the Plan filed with the Bankruptcy Court (including any amendments or supplements thereto). Such documents shall be consistent with the terms
of the Restructuring, the Restructuring Term Sheet and the Plan and acceptable in form and substance to the Parties. 
 “Prepetition
Security Agreement” means the Guaranty and Security Agreement, dated January 5, 2018, among the Debtors and the Prepetition Agent, as amended, supplemented, or otherwise modified from time to time in accordance with the terms thereof.

 “Registered Intellectual Property” means all applications, registrations and filings for Intellectual Property that have
been registered or filed with or by, or are the subject of an application before, any Governmental Entity or internet domain name registrar, including the United States Patent and Trademark Office or United States Copyright Office, including issued
Patents and Patent applications, registered Trademarks and Trademark applications, registered Copyrights and Copyright applications, and internet domain name registrations. 

  
 14 

 “Regulatory Authority” means any national or supranational Governmental
Entity, including the FDA or the EMA, with responsibility for granting any license, registrations or approvals with respect to the Products. 

“Regulatory Authorizations” means any approvals, clearances, authorizations, registrations, certifications, licenses and
permits granted by any Regulatory Authority, including any INDs, NDAs and any equivalent thereof granted by any Regulatory Authority outside of the United States. 

“Representatives” means, when used with respect to any Person, the directors, officers, partners, managers, employees,
consultants, financial advisors, accountants, counsel, investment bankers and other agents, advisors and representatives of such Person and its Subsidiaries. 

“Requisite Supporting Lenders” means, as of the relevant date, the Supporting Lenders that collectively hold greater than 50%
of the aggregate outstanding principal amount of the Prepetition Credit Agreement Claims held by Supporting Lenders. 

“Sarbanes-Oxley Act” means the Sarbanes-Oxley Act of 2002, as amended. 

“SEC” means the United States Securities and Exchange Commission. 

“Securities Act” means the Securities Act of 1933, as amended. 

“Severance Plan” means the Melinta Therapeutics, Inc. Severance Plan and Summary Plan Description, October 31, 2019.

 “Software” means any and all (a) computer programs and other software, including software implementations of
algorithms, models, and methodologies, whether in source code, object code or other form, including libraries, subroutines and other components thereof, together with input and output formats; (b) computerized databases and other computerized
compilations and collections of data or information; (c) screens, user interfaces, command structures, report formats, templates, menus, buttons and icons; (d) descriptions, flow charts, architectures, development tools, and other
materials used to design, plan, organize and develop any of the foregoing; and (e) all documentation, including development, diagnostic, support, user and training documentation related to any of the foregoing. 

“Solicitation Materials” has the meaning set forth in the definition of “Definitive Documents.” 

“Subsidiary” means with respect to any Person, any corporation, limited liability company, partnership or other organization,
whether incorporated or unincorporated, of which (a) at least a majority of the outstanding shares of capital stock of, or other Equity Interests, having by their terms ordinary voting power to elect a majority of the board of directors or
others performing similar functions with respect to such corporation, limited liability company, partnership or other organization is directly or indirectly owned or controlled by such Person or by any one or more of its Subsidiaries, or by such
Person and one or more of its Subsidiaries or (b) with respect to a partnership, such Person or any other Subsidiary of such Person is a general partner of such partnership. 

  
 15 

 “Tax” or “Taxes” means any and all U.S.
federal, state, local and non-U.S. taxes, assessments, levies, duties, tariffs, imposts and other similar charges and fees imposed by any Governmental Entity, including income, franchise, windfall or other
profits, gross receipts, property, sales, use, net worth, capital stock, payroll, employment, social security, workers’ compensation, unemployment compensation, excise, withholding, ad valorem, stamp, transfer, value-added, occupation,
environmental, disability, real property, personal property, registration, alternative or add-on minimum, or estimated tax, including any interest, penalty, additions to tax and any additional amounts imposed
with respect thereto. 
 “Tax Return” means any return, filing, report, questionnaire, information statement, claim for
refund or declaration of estimated Taxes, including any schedule or attachment thereto or any amendment thereof, filed or required to be filed with any Taxing Authority in connection with the determination, assessment or collection of any Tax, or
the administration of any laws, regulations or administrative requirements relating to any Tax, including consolidated, combined and unitary tax returns. 

“Taxing Authority” means any U.S. federal, state, local or non-U.S. Governmental
Entity or authority exercising regulatory authority in respect of taxes or responsible for the imposition of any Tax. 
 “Trade
Secrets” means trade secrets and rights in confidential or proprietary information, inventions, know-how, discoveries, methods, processes, formulae, models, methodologies, drawings, prototypes,
designs, customer lists and supplier lists. 
 “Trademarks” means trademarks, trade names, service marks, trade dress,
certification marks, collective marks, d/b/a’s, symbols, design rights and other similar designations of origin, together with the goodwill associated with or symbolized by any of the foregoing. 

“Transaction Expenses” means all fees and expenses of the Prepetition Agent, the Supporting Lenders, and each of their
advisors, that are incurred in connection with the Restructuring. 
 “Transactions” means the acquisition of the Equity
Interests of the reorganized Debtors by the Supporting Lenders in accordance with the terms hereof and the Restructuring Term Sheet. 

“Variant” means, with respect to a compound, any deuterium or fluorine analogs, and any radioisomers, enantiomers,
enantiomeric mixtures, salt forms, anhydrides, hydrates, polymorphs, metabolites or ester forms of such compound, in each case, in any formulation, including any extended release formulation. 

Section 1.2 Terms Defined Elsewhere in this Agreement. The following terms are defined elsewhere in this
Agreement, as indicated below: 
 Alternative Transaction Section 4.1(j)(ii) 

  
 16 

			
		
	Bankruptcy Code	  	Recitals
		
	Bankruptcy Court	  	Recitals
		
	Business	  	Recitals
		
	Cash Collateral Order	  	Recitals
		
	Cash Collateral Orders	  	Recitals
		
	Chapter 11 Cases	  	Recitals
		
	Company	  	Preamble
		
	Company Disclosure Letter	  	Article V
		
	Company SEC Documents	  	Section 5.6(a)
		
	Company Subsidiaries	  	Preamble
		
	Company Termination Event	  	Section 9.1(d)
		
	Consent	  	Section 5.4
		
	Debtor	  	Preamble
		
	Debtors	  	Preamble
		
	DSS	  	Preamble
		
	Effective Period	  	Section 3.1
		
	Enforceability Limitations	  	Section 5.3
		
	Exclusively Licensed IP	  	Section 5.11(a)
		
	Final Cash Collateral Order	  	Recitals
		
	Financial Statements	  	Section 5.6(e)
		
	Insurance Policies	  	Section 5.21
		
	Interfund Transfers	  	Section 7.3(d)
		
	Interim Cash Collateral Order	  	Recitals
		
	Leases	  	Section 5.13(b)
		
	Material Contracts	  	Section 5.14(a)
		
	Melinta	  	Preamble
		
	Other Motions	  	Section 4.1(b)
		
	Owned Registered Intellectual Property	  	Section 5.11(a)
		
	Parties	  	Preamble
		
	Party	  	Preamble
		
	PDIII	  	Preamble
		
	PDIV	  	Preamble
		
	Petition Date	  	Recitals
		
	Plan	  	Recitals
		
	Prepetition Agent	  	Preamble
		
	Prepetition Credit Agreement	  	Preamble
		
	Prepetition Credit Agreement Claims	  	Section 3.3
		
	Prepetition Lenders	  	Preamble
		
	Privacy and Security Policies	  	Section 5.12(b)
		
	Products	  	Recitals
		
	Restructuring	  	Recitals
		
	Restructuring Term Sheet	  	Recitals
		
	Safety Notice	  	Section 5.19(h)
		
	Supporting Lender	  	Preamble
		
	Supporting Lender Termination Event	  	Section 9.1(a)
		
	Three Day Review Pleadings	  	Section 4.1(b)
		
	Transfer	  	Section 3.3
		
	Transferee	  	Section 3.3
		
	Transferee Joinder	  	Section 3.3

  
 17 

 ARTICLE II 

DEFINITIVE DOCUMENTS 

Section 2.1 Incorporation of Exhibits and Schedules. Each of the exhibits and schedules attached hereto, including the
Restructuring Term Sheet and all exhibits thereto, are expressly incorporated by reference and made part of this Agreement as if fully set forth herein. The Restructuring Term Sheet (including each of the exhibits thereto) sets forth the material
terms and conditions of the Plan and the Restructuring. Except as otherwise provided herein, neither this Agreement, the Restructuring Term Sheet nor any provision hereof or thereof may be modified, amended, waived or supplemented except in
accordance with Section 10.14. 
 Section 2.2 Definitive Documents. The Definitive Documents,
including any amendments, supplements or modifications thereof, shall contain terms and conditions consistent in all respects with this Agreement and the Restructuring Term Sheet. The Parties acknowledge and agree that (a) the Debtors shall
provide advance draft copies of the Plan and Disclosure Statement to counsel to the Supporting Lenders at least ten (10) days prior to the date when the Debtors intend to file the Disclosure Statement or Plan, as applicable; and (b) they
will each use commercially reasonable efforts to provide advance draft copies of all other Definitive Documents and other pleadings (excluding pleadings of an administrative or ministerial nature) to counsel to the other Parties at least three
(3) Business Days prior to the date when any Party intends to file such pleading or other document, if applicable; provided, however, if circumstances reasonably prevent a Party from providing such drafts at least three
(3) Business Days prior to filing, no Party shall be precluded from filing such Definitive Document and other pleadings, but such Party shall use commercially reasonable efforts to provide a draft to the other Parties as soon as practicable
under the circumstances prior to such filing; provided further, however, that the Debtors shall not be required to provide draft copies of any declarations, retention applications, any fee statements, or any fee applications to
counsel to the Supporting Lenders. 
 ARTICLE III 

COMMITMENTS OF THE SUPPORTING LENDERS 

Section 3.1 Support of Restructuring. From the date of this Agreement and as long as this Agreement has not been terminated
pursuant to its terms (such period, the “Effective Period”), subject to the terms of this Agreement, each Supporting Lender severally agrees that it shall: 

(a) negotiate in good faith all Definitive Documents, reasonably agree to extensions of the Milestones to the extent required to accommodate
the Bankruptcy Court’s calendar, and comply with each of its other covenants and commitments set forth in this Agreement or the Restructuring Term Sheet; 

  
 18 

 (b) provide prompt written notice to the Company between the date of this Agreement and the
Effective Date of (i) the occurrence, or failure to occur, of any event of which the occurrence or failure to occur would be reasonably likely to cause any Lender Specified Representations to be untrue or inaccurate in any respect or any
other representation or warranty of the Supporting Lenders contained in this Agreement to be untrue or inaccurate in any material respect, (ii) any material breach of any covenant of the Supporting Lenders contained in this Agreement,
(iii) any event, condition, fact, or circumstance that would make the timely satisfaction of any of the conditions set forth in Article VIII impossible or unlikely, (iv) the receipt of any written notice from any
third party alleging that the consent of such party is or may be required as a condition precedent to consummation of the Transactions or (v) the receipt of any written notice from any Governmental Entity that is material to the consummation of
the Transactions; 
 (c) (i) subject to receipt of the Disclosure Statement and other Solicitation Materials approved by the Disclosure
Statement Order, timely vote, or cause to be voted, all of its Claims to accept the Plan following the commencement of solicitation of votes for the Plan, by delivering their duly executed and completed ballots accepting the Plan; (ii) refrain
from changing, revoking or withdrawing (or causing such change, revocation or withdrawal of) such vote or consent; provided, however, that such vote may be revoked (and, upon such revocation, deemed void ab initio) by such
Supporting Lender at any time following the termination of this Agreement as to such Supporting Lender pursuant to the terms hereof; and (iii) not object to, delay, postpone, challenge, reject, oppose or take any other action that would
prevent, interfere with, delay or impede, directly or indirectly, the releases and exculpations set forth in the Plan and to the extent it is permitted to elect whether to opt in or opt out of any agreed upon releases or exculpations set forth in
the Plan, to elect to opt in, and not to elect to opt out of, the releases set forth in the Plan so long as such release may be revoked (and, upon such revocation, deemed void ab initio) by such Supporting Lender at any time following the
termination of this Agreement as to such Supporting Lender pursuant to the terms hereof; 
 (d) to the extent that a legal or structural
impediment to consummation of the Plan arises outside of the jurisdiction of the Bankruptcy Court, and such legal or structural impediment does not otherwise provide the Supporting Lenders with a right to terminate this Agreement, negotiate in good
faith to address any such impediment; and 
 (e) not: 

(i) object to, delay, postpone, challenge, reject, oppose or take any other action that would prevent, interfere with, delay
or impede, directly or indirectly, in any material respect, the approval, acceptance or implementation of the Restructuring on the terms set forth herein or in the Restructuring Term Sheet; 

(ii) object to or oppose, or support any other Person’s efforts to object to or oppose, any motions filed by the Company
that are consistent with this Agreement, including any request by the Company to extend its exclusive periods to file the Plan and solicit acceptances thereof; 

  
 19 

 (iii) object to, or vote to reject, the Plan or any other Definitive
Document that comports with this Agreement; provided that the Supporting Lenders shall be entitled to object to or vote to reject the Plan or any Definitive Document on the basis that it does not comport with this Agreement; 

(iv) initiate any legal proceeding or enforce rights as holders of Claims that are inconsistent with, or that would reasonably
be expected to prevent or materially delay consummation of, the Restructuring; or 
 (v) take any actions where such taking
would be (A) inconsistent with this Agreement, the Restructuring Term Sheet or the Definitive Documents or (B) otherwise inconsistent with, or reasonably expected to prevent, interfere with or impede the implementation or consummation of,
the Restructuring. 
 Section 3.2 Rights of Supporting Lenders Unaffected. Nothing contained in this Agreement shall limit: 

(a) the rights of any Supporting Lender to appear as a party in interest in any matter to be adjudicated in order to be heard concerning any
matter arising in the Chapter 11 Cases, in each case, so long as the exercise of any such right is not inconsistent with such Supporting Lender’s obligations hereunder; 

(b) the ability of any Supporting Lender to purchase, sell, or enter into any transactions in connection with its Claims, subject to the terms
hereof and applicable Law; 
 (c) the ability of any Supporting Lender to assert or raise any objection in connection with any hearing in
the Bankruptcy Court so long as such objection is not inconsistent with such Supporting Lender’s obligations hereunder; 
 (d) any
right of any Supporting Lender to take or direct any action relating to the maintenance, protection, or preservation of any collateral so long as such action is not inconsistent with this Agreement; 

(e) subject to the terms hereof, any right of a Supporting Lender under (x) the Prepetition Credit Agreement, or that constitutes a
waiver or amendment of any provision of the Prepetition Credit Agreement or (y) any other applicable agreement, instrument or document that gives rise to a Supporting Lender’s Claims or interests, as applicable, or that constitutes a
waiver or amendment of any provision of any such agreement, instrument or document; 
 (f) the ability of any Supporting Lender to consult
with other Supporting Lenders or the Company; 

  
 20 

 (g) the ability of a Supporting Lender to enforce any right, remedy, condition, consent or
approval requirement under this Agreement, the Cash Collateral Orders, or any of the other Definitive Documents; or 
 (h) the right of any
Supporting Lender to assert and receive distributions on any Claims held by such Supporting Lender (including Claims that do not arise under the Prepetition Credit Agreement or the Cash Collateral Orders). 

Section 3.3 Transfer of Claims. During the Effective Period, no Supporting Lender shall sell, contract to sell, give, assign,
participate, hypothecate, pledge, encumber, grant a security interest in, offer, sell any option or Contract to purchase, or otherwise transfer or dispose of, any economic, voting or other rights in or to, by operation of Law or otherwise (each, a
“Transfer”) all or any portion of the Claims arising under the Prepetition Credit Agreement (“Prepetition Credit Agreement Claims”) (including granting any proxies, depositing such Prepetition Credit Agreement
Claims into a voting trust or entering into a voting agreement with respect to such Prepetition Credit Agreement Claims); provided, however, that any Supporting Lender may Transfer any of its Prepetition Credit Agreement Claims to any
Person (so long as such Transfer is not otherwise prohibited by any order of the Bankruptcy Court) that (i) agrees in writing, in substantially the form attached hereto as Exhibit C (a “Transferee
Joinder”), to be bound by the terms of this Agreement (each such transferee, a “Transferee”) or (ii) is a Supporting Lender; provided that upon any purchase, acquisition or assumption by any Supporting Lender of
any Prepetition Credit Agreement Claims, such Prepetition Credit Agreement Claims shall automatically be deemed to be subject to the terms of this Agreement. Subject to the terms and conditions of any order of the Bankruptcy Court limiting a
Transfer, the transferring Supporting Lender shall provide the Company and its counsel and the Prepetition Agent with a copy of any Transferee Joinder executed by such Transferee within one (1) Business Day following such execution. In the case
of a Transfer to a Person that is not a Supporting Lender, the Transfer shall only be effective upon execution and delivery of a Transferee Joinder in which event (A) the Transferee shall be deemed to be a Supporting Lender hereunder with
respect to all of its owned or controlled Prepetition Credit Agreement Claims and (B) the transferor Party shall be deemed to relinquish its rights (and be released from its obligations) under this Agreement solely to the extent of such
transferred Prepetition Credit Agreement Claims. With respect to Prepetition Credit Agreement Claims held by the relevant Transferee upon consummation of a Transfer, such Transferee is deemed to make all of the representations and warranties of a
Supporting Lender set forth in this Agreement. Any Transfer of any Supporting Lender’s Prepetition Credit Agreement Claim that does not comply with the foregoing shall be deemed void ab initio and the Company and each other Party shall
have the right to enforce the voiding of such Transfer. 
 ARTICLE IV 

COMMITMENTS OF THE COMPANY 

Section 4.1 Commitments of the Company. During the Effective Period, subject to the terms of this Agreement (including the terms
and conditions set forth in the Restructuring Term Sheet), including, for the avoidance of doubt, the Company’s solicitation, evaluation, negotiation, review and pursuit of Alternative Transactions to the extent set forth herein and in the
Bidding Procedures Order, the Company agrees that it shall, and shall direct its Subsidiaries and its and their respective Affiliates to: 

  
 21 

 (a) (i) use commercially reasonable efforts to seek approval of the Plan and to
complete the Restructuring; (ii) prosecute and defend any appeals relating to the Confirmation Order; (iii) support and consummate the Restructuring in a timely manner in accordance with this Agreement, including to negotiate in good faith
all Definitive Documents, coordinate its activities with the other Parties hereto in respect of all matters concerning the implementation and consummation of the Restructuring and take any and all necessary and appropriate actions in furtherance of
this Agreement, (iv) use reasonable best efforts to comply with each Milestone as set forth in Annex D to the Restructuring Term Sheet, including agreeing to the extension of such Milestones as required to accommodate
the Bankruptcy Court’s calendar; and (v) comply with each of its other covenants and commitments set forth in this Agreement or the Restructuring Term Sheet; 

(b) provide draft copies of (i) the Plan and Disclosure Statement to counsel to the Supporting Lenders at least ten (10) calendar
days prior to filing with the Bankruptcy Court, (ii) the Plan Supplement, the motion to approve the Disclosure Statement, the Solicitation Materials, any proposed Confirmation Order, any proposed amended version of the Plan or the Disclosure
Statement, all “second day” pleadings (including forms of orders thereof), and any other motions, draft orders, pleadings or briefs that are material to the Restructuring (collectively, the “Three Day Review Pleadings”)
the Company intends to file with the Bankruptcy Court to counsel to the Supporting Lenders at least two (2) Business Days prior to filing with the Bankruptcy Court, with all other motions, applications, proposed orders, pleadings and briefs
(“Other Motions”) the Company intends to file with the Bankruptcy Court to be provided to counsel to the Supporting Lenders no fewer than twenty-four (24) hours prior to filing with the Bankruptcy Court, and in each case,
consult in good faith with such counsel regarding the form and substance of any such proposed filing with the Bankruptcy Court or, to the extent such filing is required to be acceptable to the Requisite Supporting Lenders pursuant to this Agreement,
not file such filing until it is acceptable to the Requisite Supporting Lenders; provided that (x) the Debtors shall not be required to provide draft copies of any declarations, retention applications, any fee statements, or any fee
applications to counsel to the Supporting Lenders and (y) if the notice required by this Section 4.1(b) with respect to the Three Day Review Pleadings and Other Motions is not reasonably practicable with respect to any
document or pleading, the Debtors may provide such document or pleading as soon as reasonably practicable; 
 (c) timely file a formal
objection to any motion filed with the Bankruptcy Court by any Person seeking the entry of an order directing the appointment of an examiner with expanded powers or a trustee, converting the Chapter 11 Cases to cases under chapter 7 of the
Bankruptcy Code, dismissing the Chapter 11 Cases, modifying or terminating the Debtors’ exclusive right to file and/or solicit acceptances of a plan of reorganization or for relief that (x) is inconsistent with this Agreement or
(y) would, or would reasonably be expected to, frustrate the purposes of this Agreement, including by preventing the consummation of the Restructuring; 

  
 22 

 (d) timely file a formal written response in opposition to any objection filed with the
Bankruptcy Court by any Person with respect to the use of cash collateral or with respect to any of the adequate protection granted to the Prepetition Lenders pursuant to the Cash Collateral Orders or otherwise; 

(e) consult with the Supporting Lenders with respect to the assumption or rejection of executory Contracts and unexpired leases of non-residential real property; 
 (f) pay all of the Transaction Expenses consistent with
Section 10.13 of this Agreement; 
 (g) provide prompt written notice to the Supporting Lenders between the date
of this Agreement and the Effective Date of (i) the occurrence, or failure to occur, of any event of which the occurrence or failure to occur would be reasonably likely to cause any Company Specified Representations to be untrue or inaccurate
in any respect or any other representation or warranty of the Company contained in this Agreement to be untrue or inaccurate in any material respect, (ii) any material breach of any covenant of the Company contained in this Agreement,
(iii) any event, condition, fact, or circumstance that would make the timely satisfaction of any of the conditions set forth in Article VIII impossible or unlikely, (iv) the receipt of any written notice from any
third party alleging that the consent of such party is or may be required as a condition precedent to consummation of the Transactions, (iv) the receipt of any written notice from any Governmental Entity that is material to the consummation of
the Transactions, (v) the receipt of any written notice of any proceeding commenced or threatened against the Company or its Subsidiaries that would otherwise affect in any material respect the Transactions and (vi) the receipt of any
written notice of any offer to purchase any material assets of (or Equity Interests in) the Debtors other than an offer submitted in accordance with the Bidding Procedures; provided, however, that the delivery of any notice pursuant to
this Section 4.1(g) shall not limit or otherwise affect the remedies available to the party receiving such notice under this Agreement; 

(h) not be in default under the Cash Collateral Orders, subject to all applicable grace and cure periods; 

(i) consult weekly (or more frequently as reasonably requested by the Supporting Lenders) with the Supporting Lenders’ legal counsel and
financial advisor regarding the Debtors’ strategic planning, discussions, negotiations, proposals, or agreements with respect to the Restructuring; and 

(j) not: 
 (i)
object to, delay, postpone, challenge, reject, oppose or take any other action that would prevent, interfere with, delay or impede, directly or indirectly, in any material respect, the approval, acceptance or implementation of the Restructuring on
the terms set forth in the Restructuring Term Sheet; 

  
 23 

 (ii) solicit, negotiate, propose, enter into, consummate, file with the
Bankruptcy Court, vote for or otherwise knowingly support, participate in or approve any plan of reorganization, sale, proposal or offer of dissolution, winding up, liquidation, reorganization, merger or restructuring, recapitalization or
refinancing of part or all of the Company or its Indebtedness other than the Plan (each, an “Alternative Transaction”); provided, however, that nothing in this Section 4.1(j) shall in any way
limit the Debtors’ rights and obligations to solicit, evaluate, negotiate, review, pursue, and enter into definitive documentation with respect to any Alternative Transaction in accordance with the Bidding Procedures and the Bidding Procedures
Order; 
 (iii) take any actions where such taking would be (A) inconsistent with this Agreement, the Restructuring
Term Sheet, the Cash Collateral Orders or the other Definitive Documents or (B) otherwise inconsistent with, or reasonably expected to prevent, interfere with, delay or impede the implementation or consummation of, the Restructuring; 

(iv) seek to amend or modify, or file a pleading seeking authority to amend or modify, the Definitive Documents in a manner
that is inconsistent with this Agreement; 
 (v) other than the Approved KEIP, seek the payment of any amount pursuant to a
key employee incentive plan or other similar payment during the pendency of the Chapter 11 Cases, unless consented to by the Requisite Supporting Lenders; or 

(vi) file or seek authority to file any pleading inconsistent with the Restructuring or the terms of this Agreement. 

Section 4.2 Rights of the Debtors Unaffected. Nothing contained in this Agreement shall limit: 

(a) the rights of any Debtor under any applicable bankruptcy, insolvency, or similar proceeding, including appearing as a party in interest in
any matter to be adjudicated in order to be heard concerning any matter arising in the Chapter 11 Cases, in each case, so long as the exercise of any such right is not inconsistent with the Company’s obligations hereunder; 

(b) the ability of any Debtor to assert or raise any objection in connection with any hearing in the Bankruptcy Court so long as such
objection is not inconsistent with the Company’s obligations hereunder; 
 (c) any right of any Debtor to take or direct any action
relating to the maintenance, protection, or preservation of such Debtor; provided that such action is not inconsistent with this Agreement; or 

(d) the ability of any Debtor to enforce any right, remedy, condition, consent or approval requirement under this Agreement or any Definitive
Document. 

  
 24 

 ARTICLE V 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY 

Except as disclosed in (x) the Company SEC Documents publicly available prior to the date of this Agreement (but excluding any predictive, cautionary or
forward-looking disclosures contained under the captions “risk factors,” “forward-looking statements” or any similar precautionary sections and any other disclosures contained therein that are predictive, cautionary or
forward-looking in nature) or (y) the disclosure letter delivered by the Company to the Supporting Lenders simultaneously with the execution of this Agreement (the “Company Disclosure Letter”) (it being understood that any
information set forth in one section or subsection of the Company Disclosure Letter shall be deemed to apply to and qualify the other sections or subsections of this Agreement to the extent that it is reasonably apparent from a reading of such
disclosure that it also qualifies or applies to such other sections or subsections), the Company hereby represents and warrants to the Supporting Lenders as follows: 

Section 5.1 Qualification, Organization, Subsidiaries, etc. The Company and each of its Subsidiaries is a legal entity duly
organized, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of the jurisdiction of
its incorporation, organization or formation, as applicable, and has all requisite corporate or similar power and authority to own, lease and operate its properties and assets, and to carry on the Business as presently conducted by it. The Company
and each of its Subsidiaries is duly qualified to do business and is in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof)
as a foreign corporation or other entity in each jurisdiction where the ownership, leasing or operation of its assets or properties or the conduct of its portion of the Business requires such qualification, except where the failure to be so
qualified or, where relevant, in good standing (x) has not been and would not reasonably be expected to be, individually or in the aggregate, material to the Business (taken as a whole) or (y) would not reasonably be expected to prevent or
materially hinder or delay any of the Transactions or the transactions contemplated by any of the Definitive Documents or affect the ability of the Company and its Subsidiaries to perform their obligations under this Agreement, the Restructuring
Term Sheet or any of the Definitive Documents. The Company does not own, directly or indirectly, any capital stock or other Equity Interests of any Person other than the Company Subsidiaries. Prior to the date of this Agreement, the Company has made
available to the Supporting Lenders a complete and accurate copy of the organizational documents of the Company and each of its Subsidiaries as in effect on the date of this Agreement. None of the Company or its Subsidiaries is in violation of any
of the provisions of its certificate of incorporation or bylaws (or equivalent organizational documents), in each case, except for violations that (i) have not been and would not reasonably be expected to be, individually or in the aggregate,
material to the Business (taken as a whole) and (ii) would not reasonably be expected to prevent or materially hinder or delay any of the Transactions or the transactions contemplated by any of the Definitive Documents or affect the ability of
the Company or its Subsidiaries to perform their respective obligations under this Agreement, the Restructuring Term Sheet or any of the Definitive Documents. 

  
 25 

 Section 5.2 Capitalization. The authorized, issued and outstanding Equity
Interests of the Company and each of its Subsidiaries is set forth on Section 5.2 of the Company Disclosure Letter. All such Equity Interests were validly issued and are fully paid and nonassessable (except to the extent such concepts are not
applicable under the applicable Law of the Company’s or such Subsidiary’s jurisdiction of incorporation, formation or organization, as applicable). The Equity Interests of each of the Company’s Subsidiaries are owned beneficially and
of record as set forth on Section 5.2 of the Company Disclosure Letter, free and clear of any Encumbrances (other than any restrictions imposed by applicable Law) and free of preemptive rights, rights of first refusal, subscription rights or
similar right of any Person and transfer restrictions (other than transfer restrictions under applicable Law). Other than the Equity Interests reserved for issuance as set forth on Section 5.2 of the Company Disclosure Letter, none of the
Company or its Subsidiaries has any Equity Interests reserved for issuance. There are no existing (a) Equity Interests in the Company or any of its Subsidiaries other than the Equity Interests set forth on Section 5.2 of the Company
Disclosure Letter, (b) without limitation to clause (a), rights, agreements or commitments of any character obligating the Company or any of its Subsidiaries or any of their Affiliates, as applicable, to issue, transfer or sell any Equity
Interests in the Company’s Subsidiaries or securities convertible into, exchangeable or exercisable for any of the foregoing, (c) contractual obligations of the Company or any of its Subsidiaries to repurchase, redeem or otherwise acquire
any of the Equity Interests in the Company or the Company’s Subsidiaries or (d) voting trusts or similar agreements to which the Company or any of its Subsidiaries is a party with respect to the voting of the Equity Interests set forth on
Section 5.2 of the Company Disclosure Letter. 
 Section 5.3 Corporate Authority. The Company has all requisite corporate
power and authority to execute and deliver, and to cause, directly or indirectly, any of the Company’s Subsidiaries or their Affiliates to execute and deliver, as applicable, and, subject to the Company obtaining necessary Bankruptcy Court
approvals from and after the Petition Date, to carry out the Restructuring and to perform its respective obligations under this Agreement, each of the Definitive Documents and each other agreement, document or instrument contemplated hereby or
thereby to which each such Person is a party. The execution and delivery of, the consummation of the Transactions by the Company and/or any of its Subsidiaries or their applicable Affiliates have been duly and validly authorized and approved by all
requisite corporate or similar action of such Person (subject, from and after the Petition Date, to the approval of the Bankruptcy Court). The Company further represents and warrants that the respective boards of directors (or such other governing
body) for the Company and each of its Subsidiaries has approved, by all requisite action, all of the Transactions, including the terms of the Restructuring set forth in the Restructuring Term Sheet, and, subject to any necessary Bankruptcy Court
approvals, no other corporate or similar proceedings (pursuant to any such Person’s organizational documents or otherwise) on the part of any such Person is necessary to authorize the consummation of, and to consummate, the Transactions.
Subject to the Company obtaining necessary Bankruptcy Court approvals from and after the Petition Date, this Agreement and each such other document have been duly and validly executed and delivered by the Company and each of its applicable
Subsidiaries and each of their applicable Affiliates, and, assuming the due authorization, execution and delivery of this Agreement and each such other documents by the relevant Supporting Lender or its Affiliates, as applicable, constitute a legal,
valid and binding agreement of the Company and each of its applicable Subsidiaries and each of their applicable Affiliates, enforceable against each such Person in accordance with its terms, 

  
 26 

 
subject to applicable bankruptcy, insolvency, reorganization, fraudulent transfer, moratorium and similar laws affecting creditors’ rights generally and subject, as to enforceability, to
general principles of equity, including principles of commercial reasonableness, good faith and fair dealing (regardless of whether enforcement is sought in a proceeding at law or in equity) (the “Enforceability Limitations”). 

Section 5.4 Consents and Approvals. Except as expressly provided in this Agreement or in the Bankruptcy Code (including, with
respect to the Company from and after the Petition Date, the approval of the Bankruptcy Court) and Section 6.3, no consent, waiver, approval, Order, permit or authorization (including those with respect to state licensing
required to operate the Business) of, or declaration, filing or registration with, or notification to, any Governmental Entity, including in connection or compliance with the HSR Act (any of the foregoing, a “Consent”) is necessary
or required on the part of (a) the Company or any of its Subsidiaries in connection with the execution and delivery of this Agreement or any other agreement, document or instrument contemplated hereby to which the Company or any of its
Subsidiaries is a party and (b) any applicable Affiliate of the Company or any such Subsidiaries in connection with the execution and delivery of this Agreement or any other agreement, document or instrument contemplated hereby to which such
Person is a party, or in connection with, in each case of the foregoing clauses (a) and (b), the performance of such Person’s obligations hereunder and thereunder, or the consummation of the Transactions (with or without notice or lapse of
time, or both), except in each case of the foregoing clauses (a) and (b), (x) for such reports under the Exchange Act as may be required to be filed with the SEC in connection with this Agreement or the Transactions, (y) for such Consents
as may be required under applicable state securities or “blue sky” Laws and the securities Laws of any foreign country or the rules and regulations of Nasdaq and (z) for such other Consents which if not obtained or made,
(i) would not reasonably be expected to be, individually or in the aggregate, material to the Business (taken as a whole) and (ii) would not reasonably be expected to prevent or materially hinder or delay any of the Transactions or the
transactions contemplated by any of the Definitive Documents or affect the ability of the Company or its Subsidiaries to perform their respective obligations under this Agreement, the Restructuring Term Sheet or any of the Definitive Documents. 

Section 5.5 No Violations. The execution or delivery of this Agreement or any agreement, document or instrument contemplated
hereby by the Company or any of its Subsidiaries or any of their applicable Affiliates, the performance of such Person’s obligations hereunder and thereunder, and the consummation of the transactions contemplated hereby or thereby, as
applicable, do not and will not (a) conflict with or result in any violation or breach of any provisions of the certificate of incorporation, bylaws or other organizational documents of any such Person, (b) with or without notice or lapse
of time or both, conflict with or result in any breach or violation of or constitute a default under, or give rise to a right of, or result in, termination, modification, cancellation, first offer, first refusal or acceleration of any obligation or
to the loss of a benefit under any Contract to which any such Person is a party or by or to which any of their respective properties, rights or assets, or the operations or conduct of the Business, are bound or subject or (c) conflict with or
violate any Order or Law applicable to any such Person or their respective properties, rights or assets, or the operations or conduct of the Business, except in the case of clauses (b) and (c), for any conflicts, breaches, violations, defaults,
rights or results that (x) have not been and would not reasonably be expected to be, 

  
 27 

 
individually or in the aggregate, material to the Business (taken as a whole) or (y) would not reasonably be expected to prevent or materially hinder or delay any of the Transactions or the
transactions contemplated by any of the Definitive Documents or affect the ability of the Company or its Subsidiaries or their Affiliates, as applicable, to perform their obligations under this Agreement, the Restructuring Term Sheet or any of the
Definitive Documents. 
 Section 5.6 SEC Filings; Financial Statements. 

(a) The Company has timely filed with or furnished to the SEC all reports, schedules, forms, statements, prospectuses, registration statements
and other documents required to be filed with or furnished to the SEC by the Company since January 5, 2018 (collectively, together with any exhibits and schedules thereto and other information incorporated therein, the “Company SEC
Documents”). No Subsidiary of the Company is required to file any report, schedule, form, statement, prospectus, registration statement or other document with the SEC or any similar Governmental Entity in any jurisdiction. 

(b) As of its filing date (or, if amended or superseded by a filing prior to the date of this Agreement, on the date of such amended or
superseding filing), the Company SEC Documents filed or furnished prior to the date of this Agreement complied, and each Company SEC Document filed or furnished subsequent to the date of this Agreement will comply, in all material respects with the
applicable requirements of Nasdaq, the Securities Act, the Exchange Act and the Sarbanes-Oxley Act, as the case may be. 
 (c) As of its
filing date (or, if amended or superseded by a filing prior to the date of this Agreement, on the date of such amended or superseding filing), each Company SEC Document filed or furnished prior to the date of this Agreement did not, and each Company
SEC Document filed or furnished subsequent to the date of this Agreement will not, contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the
circumstances under which they were made, not misleading. 
 (d) The Company is, and since January 5, 2018 has been, in compliance in
all material respects with (i) the applicable provisions of the Sarbanes-Oxley Act and (ii) the applicable listing and corporate governance rules and regulations of Nasdaq. 

(e) The Company has made available to the Supporting Lenders copies of the following financial statements (collectively the “Financial
Statements”): (i) the audited consolidated balance sheet of the Company as of December 31, 2018 and the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity (deficit) and cash flows
for the fiscal year then ended; and (ii) the unaudited consolidated balance sheet of the Company as of September 30, 2019 and the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity
(deficit) and cash flows for the nine (9) months then ended. Subject to the notes thereto, the Financial Statements were prepared, in all material respects, in conformity with GAAP and present fairly, in all material respects, the financial
position of the Company (including its Subsidiaries) and its results of operations and cash flows as of the respective dates and for the respective periods referred to in the Financial Statements (in the case of quarterly Financial Statements,
subject to normal year-end adjustments). 

  
 28 

 (f) Since January 5, 2018, none of the Company or any of its Subsidiaries has received
any written notices from the SEC or any other Governmental Entity indicating that any of its accounting policies or practices are or may be the subject of any review, inquiry, investigation or challenge by the SEC or any other Governmental Entity.

 (g) The Company and its Subsidiaries have established and maintained in all material respects, disclosure controls and procedures (as
defined in Rule 13a-15 under the Exchange Act) designed to ensure that material information relating to the Company, including its consolidated Subsidiaries, is made known to the Company’s principal
executive officer and its principal financial officer by others within those entities, including during the periods in which the periodic reports required under the Exchange Act are being prepared. Such controls and procedures include those that:
(x) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company, (y) provide reasonable assurance that transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP and that receipts and expenditures are being made only in accordance with authorizations of management and directors of the Company and (z) provide reasonable assurance
regarding prevention or timely detection of unauthorized acquisition, use or disposition of the assets of the Company that could have a material effect on the financial statements. For purposes of this Agreement, “principal executive
officer” and “principal financial officer” shall have the meanings given to such terms in the Sarbanes-Oxley Act. 
 (h) The
Company and its Subsidiaries have established and maintained in all material respects, a system of internal controls designed to provide reasonable assurance regarding the reliability of the Company’s financial reporting and the preparation of
the Company’s financial statements for external purposes in accordance with GAAP, and the Company’s principal executive officer and principal financial officer have disclosed, based on their most recent evaluation of such internal controls
prior to the date of this Agreement, to the Company’s auditors and the audit committee of the board of directors of the Company (i) all significant deficiencies and material weaknesses in the design or operation of internal controls which
are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information and (ii) any fraud, whether or not material, that involves management or other employees who have a significant
role in internal controls. The Company has made available to the Supporting Lenders prior to the date of this Agreement a true and complete (in all material respects) summary of any disclosure of the type described in the preceding sentence made by
management to the Company’s auditors and audit committee during the period beginning January 5, 2018 and ending as of the date of this Agreement. For purposes of this Section 5.6, “internal controls”
means internal controls over financial reporting (as defined in Rule 13a-15 under the Exchange Act). 

(i) Since January 5, 2018, each of the principal executive officer and principal financial officer of the Company (or each former
principal executive officer and principal financial officer of the Company, as applicable) has made all certifications required by Rules 13a-14 and 15d-14 under the
Exchange Act and Sections 302 and 906 of the Sarbanes-Oxley Act and any related rules and regulations promulgated by the SEC and Nasdaq, and the statements contained in any such certifications are true and complete in all material respects as of the
date on which they were made. 

  
 29 

 Section 5.7 No Undisclosed Liabilities. There are no liabilities or obligations
of the Company or any of its Subsidiaries of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable or otherwise, that would be required by GAAP to be reflected on the consolidated balance sheet of the Company and its
Subsidiaries, other than (a) liabilities or obligations disclosed and provided for in the Financial Statements or in the notes thereto, (b) liabilities or obligations incurred in the ordinary course of business consistent with past
practice since September 30, 2019, (c) liabilities arising in connection with the Transactions, the Restructuring or the Chapter 11 Cases or (d) other liabilities or obligations that (x) have not been and would not reasonably be
expected to be, individually or in the aggregate, material to the Business (taken as a whole) or (y) would not reasonably be expected to prevent or materially hinder or delay any of the Transactions or the transactions contemplated by any of
the Definitive Documents or affect the ability of the Company or its Subsidiaries to perform their obligations under this Agreement, the Restructuring Term Sheet or any of the Definitive Documents. There are no
off-balance sheet arrangements of any type required to be disclosed pursuant to Item 303(a)(4) of Regulation S-K promulgated under the Securities Act that have not been
so disclosed in the Company SEC Documents. 
 Section 5.8 Absence of Certain Changes. Except to the extent arising out of or
relating to the Chapter 11 Cases, this Agreement or the Transactions, from January 5, 2018 through the date of this Agreement, the Business has been conducted in all material respects in the ordinary course of business consistent with past
practice, and there has not been: 
 (a) any material damage, destruction or other casualty loss with respect to any asset or property
owned, leased or otherwise used by the Company or its Subsidiaries, whether or not covered by insurance; 
 (b) any declaration, setting
aside or payment of any dividend or other distribution with respect to any shares of capital stock or other Equity Interests of the Company or its Subsidiaries (except for dividends or other distributions by any direct or indirect wholly owned
Subsidiary to such Person or to any wholly owned Subsidiary of such Person), or any repurchase, redemption or other acquisition by the Company or its Subsidiaries of any outstanding shares of capital stock or other Equity Interests of the Company or
its Subsidiaries; 
 (c) any material change in any method of accounting or accounting practice by the Company or its Subsidiaries; 

(d) (i) any material increase in the compensation payable or to become payable to the officers or employees of any of the Company or its
Subsidiaries or material increases in the benefits of such officers or employees (except for increases in the compensation of non-officer employees in the ordinary course of business and consistent with past
practice), (ii) any entrance into, adoption, material amendment or termination of any Debtor Plan (or any arrangement that would have been a Debtor Plan were it in effect as of the date of this Agreement) that is or would be material to the
Company and its Subsidiaries, taken as a whole or (iii) any actions taken by the Company and its Subsidiaries to accelerate the vesting or lapsing of restrictions or payment, or fund or in any other way secure the payment, of any material
compensation or benefits under any Debtor Plan, taken as a whole, except, in each case, to the extent required by applicable Laws; 

  
 30 

 (e) any agreement to do any of the foregoing; or 

(f) any event, development, change or effect that has had or would reasonably be expected to have, individually or in the aggregate, a
Material Adverse Effect. 
 Section 5.9 Brokers or Finders. Other than Jefferies LLC, none of the Company or its Subsidiaries
has employed or engaged any investment banker, broker or finder who is entitled to any brokerage, finder’s or other fee or any commission in connection with this Agreement, the Restructuring Term Sheet, the Definitive Documents, the
transactions contemplated by this Agreement or any other agreement, document or instrument contemplated hereby or thereby based upon arrangements made by or on behalf of the Company or its Subsidiaries or any of their Affiliates. 

Section 5.10 Litigation. Except (x) as set forth on Section 5.10 of the Company Disclosure Letter and (y) for the
Chapter 11 Cases, there are no Causes of Action pending or, to the Knowledge of the Debtors, threatened against any of the Company or its Subsidiaries or any of their respective properties, rights or assets, or that involves or relates to any
of the Transactions or the operations or conduct of the Business, except those which have not been and would not reasonably be expected to be, individually or in the aggregate, material to the Company or any of its Subsidiaries. None of the Company,
any of its Subsidiaries, any applicable Affiliates or the Business is subject to any outstanding Order, and there are no judgments or decrees of or settlement agreements with, any Governmental Entity, except those which have not been and would not
reasonably be expected to be, individually or in the aggregate, material to the Company and its Subsidiaries. Notwithstanding the foregoing, no representation or warranty is made under this Section 5.10 in respect of any
(i) Intellectual Property matters, which are addressed in Section 5.11, (ii) employee benefits matters, which are addressed in Section 5.16, (iii) environmental matters, which are addressed in
Section 5.18, (iv) healthcare regulatory matters, which are addressed in Section 5.19 or (v) Tax matters, which are addressed in Section 5.20. 

Section 5.11 Intellectual Property. 

(a) Section 5.11(a) of the Company Disclosure Letter sets forth a true and complete list, as of the date hereof, of all Registered
Intellectual Property that is owned by the Company or any of its Subsidiaries (the “Owned Registered Intellectual Property”), setting forth (A) the legal and record owner(s), (B) the registration or application number (as
applicable), (C) the registration or application date (as applicable) and (D) the jurisdiction in which such item is registered or pending or, with respect to internet domain names, the applicable internet domain name registrar. All Owned
Registered Intellectual Property (other than Registered Intellectual Property constituting applications) is subsisting, valid, and to the Knowledge of the Debtors, enforceable. There is no, and since the Applicable Date, there has been no, Cause of
Action or notice of any objection or claim asserted in writing or, to the 

  
 31 

 
Knowledge of the Debtors, threatened by any Person, seeking to cancel, materially limit, or challenge the ownership, validity or enforceability of any Owned Registered Intellectual Property, and
except as has not and will not irreversibly impair the validity or enforceability of any Owned Registered Intellectual Property (or, to the Knowledge of the Debtors, any Intellectual Property licensed exclusively to the Company or any of its
Subsidiaries that is material to the conduct of the Business (“Exclusively Licensed IP”) and for which the Company is responsible for prosecution and maintenance) and adversely impact the Business, the Company and each of its
applicable Subsidiaries have made timely payment of all registration, maintenance, renewal and filing fees required with respect to such Registered Intellectual Property. For the purposes of this Section 5.11 and
Section 5.12, “Applicable Date” means, (i) solely in connection with matters concerning businesses or Products acquired from The Medicines Company, January 5, 2018, and (ii) in connection
with matters concerning all other portions of the Business, January 1, 2017. 
 (b) The Company and the Company Subsidiaries solely and
exclusively own all Company Intellectual Property free and clear of any Encumbrances (other than Permitted Encumbrances), and no other Person has any joint ownership interest in or to any of the Company Intellectual Property. None of the Company
Intellectual Property (or, to the Knowledge of the Debtors, any Exclusively Licensed IP) is subject to any Order adversely affecting or restricting the validity or enforceability thereof, or any of the Company’s or any of its Subsidiaries’
ownership or use thereof. 
 (c) The Licensed IP and Company Intellectual Property collectively constitute all of the material Intellectual
Property used in or held for use in the conduct of the Business as currently conducted (provided that the foregoing is not a representation or warranty with respect to infringement, misappropriation or other violation of Intellectual Property), all
of which material Intellectual Property rights shall survive the consummation of the transactions contemplated by this Agreement without termination or substantial acceleration of any obligation thereunder. No material Company Intellectual Property
is owned by any Subsidiary of the Company other than one or more of the Company Subsidiaries, and all material Licensed IP is licensed to one or more of the Company or its Subsidiaries. 

(d) Except as has not resulted in, and would not reasonably be expected to result in, material liability or disruption to the Business, since
the Applicable Date, (i) neither (A) the conduct of the Business, nor (B) the current administration, use, supply, manufacture, import, marketing, commercialization or other exploitation of any of the Products by (1) the Company or
any of its Subsidiaries, or, (2) to the Knowledge of the Debtors, any of their respective customers or end-users (solely in connection with such Person’s use or administration of the Product
substantially in accordance with its labelling or as otherwise intended to be used or administered), or suppliers or contractors (solely in their capacity as such on behalf of the Company or any of its Subsidiaries and in accordance with their
contractual obligations to the Company or its Subsidiary, as applicable), has infringed, misappropriated, or violated any Intellectual Property of any other Person, (ii) to the Knowledge of the Debtors as of the date hereof, no Person has
infringed, misappropriated, or otherwise violated any Company Intellectual Property and (iii) none of the Company nor any of its Subsidiaries have sent or received any written claim, notice, demand to license, or similar communication alleging
or suggesting any infringement, misappropriation, or other violation of the type described in clauses (i) or (ii) of this Section 5.11(d). 

  
 32 

 (e) The Company and each of its Subsidiaries have, at all times since the Applicable Date,
taken commercially reasonable efforts to protect the confidentiality of all material Trade Secrets that are owned, used or held by any of the Company or any of its Subsidiaries, and no such material Trade Secrets have been used by, disclosed to or
otherwise discovered by any Person except pursuant to valid and enforceable non-disclosure and confidentiality agreements (or obligations arising by operation of Law) that have not, to the Knowledge of the
Debtors, been breached by such Persons in a manner that has been or would reasonably be expected to be material and adverse to the Business, or would otherwise result in the loss of any trade secret rights in any trade secrets included within such
Trade Secrets. 
 (f) Each Person who contributed to the development or creation of any material Company Intellectual Property within the
scope of their employment for, or work requested by or on behalf of, the Company or any of its Subsidiaries has executed a valid and enforceable agreement containing an irrevocable present assignment conveying to one or more of the Company or its
Subsidiaries (or has otherwise assigned by operation of Law) all of such Person’s right, title and interest in and to such Intellectual Property. To the Knowledge of the Debtors, no current or former employee or contractor of any of the Company
of any of its Subsidiaries retains or claims to retain any ownership interest in or to any Company Intellectual Property. 
 (g) None of the
Company Intellectual Property is subject to any obligation under any Contract or other present or contingent obligation as a result of being developed using any funding or support from, or any arrangement with, a Governmental Entity or nonprofit
organization. 
 Section 5.12 Data Privacy and Cybersecurity; IT Assets. 

(a) The Company IT Assets are sufficient for the current and currently anticipated needs of the Business, and since the Applicable Date, there
has been no unauthorized access to or unauthorized use of any (i) IT Assets owned, used or held for use by the Company or any of its Subsidiaries, (ii) information of, or collected, stored or processed by or on behalf of, the Company or
its Subsidiaries and stored or processed by such IT Assets, or (iii) confidential or proprietary information of the Company or any of its Subsidiaries, in each case, in a manner that, individually or in the aggregate, has resulted in or would
reasonably be expected to result in material liability or disruption of the Business; provided that the foregoing representations with respect to IT Assets owned or controlled by third-party service providers are given only to the Knowledge
of the Debtors. To the Knowledge of the Company, none of the IT Assets owned, used or held for use by the Company or any of its Subsidiaries since the Applicable Date contain or make available any material disabling codes or instructions, spyware,
Trojan horses, worms, viruses or other software routines that facilitate or cause unauthorized access to, or disruption, impairment, disablement, or destruction of, Software, data or other materials. 

  
 33 

 (b) The Company and each of its Subsidiaries have established and implemented appropriate
written policies and organizational, physical, administrative and technical measures regarding privacy, cyber security and data security, and are no less protective than (i) reasonable practices in the industry or (ii) any written
commitments of the Company or any of its Subsidiaries (such policies and measures, collectively, the “Privacy and Security Policies”). 

(c) To the Knowledge of the Company, at all times since the Applicable Date, except as has not resulted in, and would not reasonably be
expected to result in, individually or in the aggregate, material liability or an obligation to notify any Governmental Entity, (i) the Company and each of its Subsidiaries have complied in all material respects with all of their respective
Privacy and Security Policies and contractual obligations, and with all applicable Laws (including (A) the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical
Health Act of 2009, and their implementing regulations and agency guidance and (B) any other applicable state or foreign privacy laws), in each case, regarding Personal Information, including with respect to the collection, use, storage,
processing, transmission, transfer (including cross-border transfers), disclosure and protection of Personal Information and (ii) no Person has gained unauthorized access to or misused any such Personal Information. 

Section 5.13 Real Property Leases. 

(a) None of the Company or any of its Subsidiaries owns any real property. 

(b) Section 5.13(b) of the Company Disclosure Letter sets forth a complete and correct list, as of the date of this
Agreement, of each Contract pursuant to which the Company or any of its Subsidiaries leases, subleases or occupies any real property (the “Leases”). None of the Company or any of its Subsidiaries has subleased, licensed or otherwise
granted any Person the right to use or occupy any real property subject to a Lease or any material portion thereof. Each Lease is valid, binding and in full force and effect, subject to the Enforceability Limitations, and no uncured default of a
material nature on the part of the Company or any of its Subsidiaries or, to the Knowledge of the Debtors, the landlord thereunder exists with respect to any Lease. The Company and its Subsidiaries have good and valid leasehold interests in or
contractual rights to use or occupy, subject to the terms of the applicable Lease, each real property subject to the Leases. 

Section 5.14 Material Contracts. 

(a) Section 5.14(a) of the Company Disclosure Letter contains a complete and correct list, as of the date of this
Agreement, of each Contract described below in this Section 5.14(a) under which the Company or any of its Subsidiaries has any current or future rights, responsibilities, obligations or liabilities (in each case, whether
contingent or otherwise) or to which the Company or any of its Subsidiaries is a party or to which any of their respective properties or assets is subject, other than the Debtor Plans listed on Section 5.16(a) of the
Company Disclosure Letter (all Contracts of the type described in this Section 5.14(a), whether or not set forth on Section 5.14(a) of the Company Disclosure Letter, being referred to herein as the
“Material Contracts”): 

  
 34 

 (i) requires expenditures by the Company or any of its Subsidiaries
involving consideration in excess of one hundred thousand dollars ($100,000) in the next twelve (12)-month period; 
 (ii)
provides for payments to be received by the Company or any of its Subsidiaries in excess of one hundred thousand dollars ($100,000) in any twelve (12)-month period; 

(iii) relates to the incurrence by the Company or any of its Subsidiaries of any Indebtedness or any capitalized lease
obligations in excess of fifty thousand dollars ($50,000); 
 (iv) relates to the acquisition or disposition outside the
ordinary course of business of any assets or any business, or any capital stock of any enterprise (whether by merger, sale or purchase of stock, sale or purchase of assets or otherwise) entered into in the past three (3) years, in each case, in
excess of one hundred thousand dollars ($100,000); 
 (v) relates to the future acquisition or disposition of any material
assets or properties (whether by merger, sale or purchase of stock, sale or purchase of assets or otherwise, including any option to acquire, sell, lease or license any material assets or properties of the Business), other than (A) in the
ordinary course of business consistent with past practice, (B) as contemplated by this Agreement, the Restructuring Term Sheet or any Definitive Document or (C) to the extent permitted under applicable Law, any non-disclosure or similar agreement entered into in connection with the process by which the Company or any of its Subsidiaries, any of their respective Affiliates or any Representatives of any of the foregoing
solicited, discussed or negotiated strategic alternatives prior to the date of this Agreement (including the Transactions or any other transaction prior to the date of this Agreement); 

(vi) is a joint venture, profit-sharing, partnership, collaboration, co-promotion,
commercialization, research, development or other similar agreement involving the sharing of profits or expenses (other than clinical trial agreements, contract manufacturing agreements or other similar subcontracting arrangements entered into in
the ordinary course of business); 
 (vii) is a Lease; 

(viii) (A) may require the Supporting Lenders to pay milestones, royalties or other contingent payments based on any
research, testing, development, regulatory filings or approval, sale, distribution, marketing, commercial manufacture or other similar occurrences, developments, activities or events with respect to any Product, in each case, which payments are in
an amount having an expected value in excess of fifty thousand dollars ($50,000) during the fiscal year ending December 31, 2019 or any fiscal year thereafter or (B) grants to any Person a right of first refusal, right of first
negotiation, option to purchase, option to license, or any other similar rights with respect to any Product; 

  
 35 

 (ix) requires the Company or any of its Subsidiaries to purchase from a
third Person their total requirements of any products or services; 
 (x) with any Governmental Entity; 

(xi) (A) limits or purports to limit, in any material respect, the freedom of the Business to engage or compete in any
line of business or with any Person or in any geographic area, (B) contains exclusivity or “most favored nation” obligations in favor of any Person other than the Company or its Subsidiaries or restrictions to which the Business is
subject or (C) contains any other provisions restricting or purporting to restrict the ability of the Company or its Subsidiaries to sell, market, distribute, promote, manufacture, develop, commercialize, or test or research the Products,
directly or indirectly through third parties (other than any such restrictions or purported restrictions that have a de minimis effect on the Business); 

(xii) is a material Contract pursuant to which the Company or any of its Subsidiaries grants or receives any license, covenant
not to sue or similar right with respect to, or governs or restricts the development, ownership, use, practice or enforcement of, any Intellectual Property (other than (A) non-exclusive licenses to use
Software on standardized terms that are generally commercially available and (B) clinical trial agreements, contract manufacturing agreements, material transfer agreements, and other Contracts entered into in the ordinary course of business, in
each case, in which grants of rights with respect to Intellectual Property are nonexclusive and incidental to performance under such Contract); 

(xiii) relates to sales and distribution activities conducted by a third-party wholesaler or distributor that are material to
the Business; 
 (xiv) relates to the ongoing supply or manufacturing of clinical and commercial quantities of any of the
Products, the termination of which would reasonably be expected to be material to the Business (taken as a whole); 
 (xv)
other than the Contracts described in Section 5.14(a)(iii), under which the Company or any of its Subsidiaries or any of their Affiliates have borrowed or loaned money, or any note, bond, indenture, mortgage or any
guarantee of such indebtedness, in each case, relating to amounts in excess of one hundred thousand dollars ($100,000); 

(xvi) relates to any settlement or stipulation of any Cause of Action against the Company or any of its Subsidiaries by any
other Person, other than settlement agreements for cash that do not exceed twenty-five thousand dollars ($25,000) individually as to any such settlement or stipulation (excluding amounts paid by insurers) or one hundred thousand dollars ($100,000)
individually as to any such settlement or stipulation (including any amounts paid by insurers), entered into since January 5, 2018; and 

  
 36 

 (xvii) provides for indemnification of any officer, director or employee of
the Company or its Subsidiaries or any of their Affiliates other than in the ordinary course of business. 
 (b) True and complete copies of
each Material Contract, together with all amendments, modifications or supplements thereto, as of the date of this Agreement have been made available to the Supporting Lenders. None of the Company or any of its Subsidiaries has received any written
notice of termination (or intent to terminate) with respect to a Material Contract from any third Person party to such Material Contract. No event has occurred which, with the passage of time or the giving of notice, or both, would constitute a
default under or a violation of any Material Contract or would cause the acceleration of any obligation of the Company or any of its Subsidiaries or their applicable Affiliates or the creation of an Encumbrance (other than Permitted Encumbrances)
upon any assets or properties of the Company or any of its Subsidiaries, except for such events that have not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. To the Knowledge of the
Debtors, as of the date of this Agreement, no other party to any Material Contract is in breach of or default under the terms of any Material Contract where such breach or default has had or would reasonably be expected to have, individually or in
the aggregate, a Material Adverse Effect. Each Material Contract is a valid, binding and enforceable obligation of the applicable the Company or its applicable Subsidiaries or their applicable Affiliates party thereto and, to the Knowledge of the
Debtors, of each other party thereto, and is in full force and effect, subject to the Enforceability Limitations. 
 Section 5.15
Compliance with Laws; Anticorruption; Permits; Trade Compliance. 
 (a) The Company and each of its Subsidiaries and their
applicable Affiliates are, and since January 5, 2018 have been, operating the Business in compliance with all applicable Laws and Orders, including 42 U.S.C. § 1320a-7b (Anti-Kickback Statute), 18
U.S.C. § 1347 (Health Care Fraud), 31 U.S.C. § 3729-33 (False Claims Act) and other applicable Laws and Orders relating to healthcare compliance and protection of animal welfare, except as has not
had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Since January 5, 2018, none of the Company or its Subsidiaries, nor any of their applicable Affiliates, has received any written
notice of or, to the Knowledge of the Debtors, been charged with any violation of any Laws, except as has not been and would not reasonably be expected to be, individually or in the aggregate, material to the Business (taken as a whole). 

(b) The Company and its Subsidiaries and their applicable Affiliates are, and since January 5, 2018, have been operating the Business in
compliance with the U.S. Foreign Corrupt Practices Act and any other applicable anticorruption Laws, except where the failure to be in compliance has not been and would not reasonably be expected to be, individually or in the aggregate, material to
the Business (taken as a whole). Since January 5, 2018, none of the Company or its Subsidiaries, nor any of their applicable Affiliates, nor to the Knowledge of the Debtors, any officer or director of any of the foregoing, while acting at
the direction of such Person, (a) has made, paid or received any unlawful bribes, kickbacks or other similar payments or (b) has made or paid any contributions, directly or indirectly, to a domestic or foreign political party or candidate,
except, in each case, as has not been and would not reasonably be expected to be, individually or in the aggregate, material to the Business (taken as a whole). 

  
 37 

 (c) The Company and its Subsidiaries have all Business Permits, except where the failure to
possess such Business Permits has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. None of the Company or its Subsidiaries, nor any of their applicable Affiliates, is in default or
violation of any term, condition or provision of any Business Permit, except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Except as has not had and would not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect, all Business Permits are valid and in full force and effect, subject to the Enforceability Limitations, and, to the Knowledge of the Debtors, no condition exists that
with notice or lapse of time or both would constitute a default of any term, condition or provision of any such Business Permits to which the Company or any of its Subsidiaries or any of their applicable Affiliates is a party. Since
January 5, 2018, none of the Company or its Subsidiaries, or any of their applicable Affiliates, has received any written notice of any Cause of Action or investigation relating to the revocation, nonrenewal, suspension or modification of
any Business Permit, except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 

(d) Except as has not and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, the Company
and its Subsidiaries and their applicable Affiliates are, and since January 5, 2018, have been in compliance with: (i) all Laws or regulations regarding the importation of goods, including the U.S. import laws administered by U.S. Customs
and Border Protection; and (ii) all other applicable Laws, including the Export Administration Regulations administered by the U.S. Department of Commerce. Except as has not and would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect, none of the Company or its Subsidiaries nor any of their applicable Affiliates, nor to the Knowledge of the Debtors, any officer or director of any of the foregoing Persons, is (i) a person or entity with
whom U.S. persons or entities are restricted from doing business under regulations of OFAC (including those named on OFAC’s Specially Designated and Blocked Persons List) or under any statute, executive order (including the September 24,
2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism), regulation, or other governmental action, (ii) a “specially designated global terrorist” or other
person listed in Appendix A to Chapter V of 31 C.F.R., as the same has been from time to time updated and amended or (iii) a person either (A) included within the term “designated national” as
defined in the Cuban Assets Control Regulations, 31 C.F.R. Part 515 or (B) designated under Sections 1(a), 1(b), 1(c) or 1(d) of Executive Order No. 13224, 66 Fed. Reg. 49079 (published September 25, 2001) or a person similarly
designated under any related enabling legislation or any other similar executive orders. 

  
 38 

 Section 5.16 Employee Benefit Matters. 

(a) Section 5.16(a) of the Company Disclosure Letter sets forth a complete and correct list of each Debtor Plan. With respect to each
Debtor Plan, the Company has made available to the Supporting Lenders, to the extent applicable, accurate and complete copies of (i) the Debtor Plan document, including any amendments thereto, and all related trust documents, insurance
contracts or other funding vehicles, (ii) a written description of such Debtor Plan if such plan is not set forth in writing, (iii) the most recently prepared actuarial report, (iv) all material correspondence to or from any
Governmental Entity received since January 5, 2018 with respect to any Debtor Plan, (v) the most recent summary plan description together with any summaries of all material modifications thereto, (vi) the most recent IRS determination
or opinion letter issued and (vii) the most recent annual report (Form 5500 or 990 series and all schedules and financial statements attached thereto). 

(b) (i) Each Debtor Plan (including any related trusts) has been established, operated and administered in accordance with its terms and
in compliance with applicable Law, including ERISA and the Code, (ii) all contributions or other amounts payable by the Company or any of its Subsidiaries with respect to any Debtor Plan in respect of current or prior plan years have been paid
or accrued in accordance with generally accepted accounting principles and (iii) there are no pending or, to the Knowledge of the Debtors, threatened claims (other than routine claims for benefits) or proceedings by a Governmental Entity by, on
behalf of or against any Debtor Plan or any trust related thereto which would reasonably be expected to result in any material liability to the Company or any of its Subsidiaries. 

(c) Each ERISA Plan that is intended to be qualified under Section 401(a) of the Code has been determined by the IRS to be qualified
under Section 401(a) of the Code and, to the Knowledge of the Debtors, nothing has occurred that would adversely affect the qualification or tax exemption of any such Debtor Plan. With respect to any ERISA Plan, none of the Company or any of
its Subsidiaries has engaged in a transaction in connection with which the Company or any of its Subsidiaries reasonably could be subject to either a civil penalty assessed pursuant to Section 409 or 502(i) of ERISA or a tax imposed pursuant to
Section 4975 or 4976 of the Code. 
 (d) None of the Company or any of its Subsidiaries nor any ERISA Affiliate has, within the six
(6)-year period prior to the date of this Agreement, ever maintained, established, sponsored, participated in, contributed to, or been obligated to contribute to, or otherwise incurred any obligation or liability (including any contingent liability)
under any “multiemployer plan” (as defined in Section 3(37) of ERISA) or any plan that is subject to Section 302 or Title IV of ERISA or Section 412 of the Code. None of the Company or any of its Subsidiaries nor any ERISA
Affiliate has any actual or potential withdrawal liability for any complete or partial withdrawal (as defined in Sections 4203 and 4205 of ERISA) from any multiemployer plan. 

(e) Except as required by applicable Law, no Debtor Plan provides retiree or post-employment medical, disability, life insurance or other
welfare benefits to any Person, and none of the Company or any of its Subsidiaries has any obligation to provide such benefits. To the extent that the Company or any of its Subsidiaries sponsors such plans, the Company or the applicable Subsidiary
has reserved the right to amend, terminate or modify at any time each Debtor Plan that provides retiree or post-employment disability, life insurance or other welfare benefits to any Person. 

  
 39 

 (f) Neither the execution and delivery of this Agreement, shareholder or other approval of
this Agreement nor the consummation of the transactions contemplated by this Agreement, whether alone or in combination with any other event, will (i) entitle any current or former employee, director, officer or independent contractor of the
Company or any of its Subsidiaries to severance pay or any material increase in severance pay, (ii) accelerate the time of payment or vesting or materially increase the amount of compensation due to any such current or former employee,
director, officer or independent contractor, (iii) directly or indirectly cause the Company or any of its Subsidiaries to transfer or set aside any assets to fund any material benefits under any Debtor Plan, (iv) otherwise give rise to any
material liability under any Debtor Plan or (v) limit or restrict the right to merge, materially amend, terminate or transfer the assets of any Debtor Plan on or following the Effective Date. 

(g) Neither the Company nor any of its Subsidiaries has any obligation to provide, and no Debtor Plan or other agreement provides any
individual with the right to, a gross up, indemnification, reimbursement or other payment for any excise or additional taxes, interest or penalties incurred pursuant to Section 409A or Section 4999 of the Code or due to the failure of any
payment to be deductible under Section 280G of the Code. 
 (h) No Debtor Plan is maintained outside the jurisdiction of the United
States or covers any employees or other service providers of the Company or any of its Subsidiaries who reside or work outside of the United States. 

Section 5.17 Labor Matters. 

(a) The Company has made available to the Supporting Lenders a true, correct and complete list, by employee identification number, of all
employees employed by the Company and its Subsidiaries on the date of this Agreement, identifying as to each a job title, years of service, current amount or rate of compensation and location of employment. 

(b) As of the date of this Agreement, neither the Company nor any of its Subsidiaries is a party to, or bound by, any collective bargaining
agreement or other agreement with any labor union or like organization, and to the Knowledge of the Debtors, there are no activities or proceedings by any individual or group of individuals, including representatives of any labor organizations, or
labor unions, to organize any employees of the Company or any of its Subsidiaries. As of the date of this Agreement, there is no pending or, to the Knowledge of the Debtors, threatened labor strike, slowdown, lockout or work stoppage, unfair labor
practice or other labor dispute, or labor arbitration or grievance. 
 (c) The Company and each of its Subsidiaries is in compliance in all
material respects with all applicable Laws respecting labor, employment and employment practices, terms and conditions of employment, wages and hours, and occupational safety and health. Neither the Company nor any of its Subsidiaries has incurred
any liability or obligation under the Worker Adjustment and Retraining Notification Act of 1988, as amended, and the regulations promulgated thereunder or any similar state, local or foreign Law relating to plant closings or mass layoffs that
remains unsatisfied. 

  
 40 

 Section 5.18 Environmental Matters. 

(a) Except as has not and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect: 

(i) each real property operated by the Company or any of its Subsidiaries and used in the conduct of their respective
businesses: (i) is in compliance with all applicable Environmental Laws, except as has not and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect; (ii) is not the subject of any pending
written notice from any Governmental Entity alleging the violation of any applicable Environmental Law; (iii) is not currently subject to any Orders arising under any Environmental Law; and (iv) has not had any emissions or discharges of
Hazardous Substances except as permitted under applicable Environmental Laws; 
 (ii) no order, decree, settlement or lien
is pending or, to the Knowledge of the Debtors, threatened, against the Company or any of its Subsidiaries relating to Liability under any Environmental Law that has not been remedied as of the date of this Agreement; and 

(iii) there are no other circumstances or conditions that would reasonably be expected to result in any claims, liability,
investigations, costs or restrictions on the ownership, use, or transfer of the Company’s or any of its Subsidiaries’ assets or properties in connection with any Environmental Law. 

(b) The Company has made available to the Supporting Lenders copies of all environmental reports, studies, assessments, sampling data,
memoranda and other information in its possession. 
 Section 5.19 FDA and Healthcare Regulatory Matters. 

(a) (i) Each of the Company and its Subsidiaries is in material compliance with all applicable Health Laws that affect the Business,
Products, properties, assets and activities of the Company or such Subsidiary, as applicable; (ii) as of the date of this Agreement, none of the Company or any of its Subsidiary has received any written notice from any Regulatory Authority
(A) withdrawing any Regulatory Authorization for any of the Products or (B) alleging any material violation of any Health Law; (iii) there are no Governmental Entity investigations (except routine audits), suits, claims, actions or
proceedings pending, or to the Knowledge of the Debtors, threatened against the Company or any of its Subsidiaries with respect to any of the Products or alleging any violation by the Company or any of its Subsidiaries or the Products of any such
Health Law; (iv) there is no act, omission, event, or circumstance of which the Company and its Subsidiaries have knowledge that would reasonably be expected to give rise to or form the basis for any civil, criminal or administrative action,
suit, demand, claim, complaint, hearing, investigation, demand letter, warning letter, untitled letter, proceeding or request for information or any liability (whether actual or contingent) for failure to comply with Health Laws; and
(v) neither the Company nor its Subsidiaries, nor, to the Knowledge of the Debtors, any director, officer, employee or contractor of the Company or its Subsidiaries, has made any voluntary self-disclosure to any Governmental Entity regarding
any potential material non-compliance with any applicable Health Law. 

  
 41 

 (b) Each of the Company and its Subsidiaries holds all Regulatory Authorizations required
under any applicable Health Law to research, develop, test, manufacture, handle, label, package, store, supply, promote, distribute, market, commercialize, import, export, and sell the Products and otherwise conduct Business as presently conducted.
With respect to such Regulatory Authorizations, (i) all are in full force and effect, (ii) all are in good standing, valid and enforceable, (iii) all applications, modifications, submissions, information, reports, statistics, data,
and other conclusions utilized as the basis for the Regulatory Authorizations are true, complete, and correct in all material respects and (iv) any necessary or required updates, changes, corrections or modifications to such Regulatory
Authorizations have been submitted to the applicable Regulatory Authorities. The Company has made available to the Supporting Lenders true and complete copies of all active and pending Regulatory Authorizations submitted by the Company and its
Subsidiaries to any Regulatory Authority relating to the Products and/or necessary to research, develop, test, manufacture, handle, label, package, store, supply, promote, distribute, market, commercialize, import, export, and sell the Products and
otherwise conduct Business as presently conducted. 
 (c) The Products have been researched, developed, tested, manufactured, handled,
labeled, packaged, stored, supplied, promoted, distributed, marketed, commercialized, imported, exported, and sold by or on behalf of the Company and its Subsidiaries, as applicable, in material compliance with all applicable Health Laws. 

(d) All pre-clinical studies and clinical trials conducted or being conducted with respect to the
Products by, or on behalf of, the Company or any of its Subsidiaries have been and are being conducted in material compliance with the FDA’s Good Clinical Practices and Good Laboratory Practices requirements, including regulations under 21
C.F.R. Parts 50, 54, 56, 58 and 312, and applicable guidance documents, as amended from time to time, the Animal Welfare Act, all applicable similar Health Laws in other jurisdictions, all Health Laws relating to protection of human subjects, and
the required experimental protocols, procedures and controls. No clinical trial conducted by, or on behalf of, the Company or any of its Subsidiaries has been terminated or suspended by any Regulatory Authority and neither the Company nor any of its
Subsidiaries has received any notifications or other communications from the FDA, any other Regulatory Authority, any institutional review board, ethics committee or safety monitoring committee raising any issues that would reasonably result in a
clinical hold or that would otherwise reasonably be expected to delay or materially restrict any clinical studies proposed or currently conducted by, or on behalf of, the Company or any of its Subsidiaries, or in which the Company or any of its
Subsidiaries has participated and, to the Knowledge of the Debtors, no such action has been threatened against the Company or any of its Subsidiaries. With respect to each Product, the Company has made available to the Supporting Lenders complete
and accurate copies of all material clinical and preclinical data in the possession of the Company and its Subsidiaries and all material written correspondence that exists as of the date of this Agreement among the Company or any of its Subsidiaries
and the applicable Regulatory Authorities (including letters, memoranda and emails). 

  
 42 

 (e) None of the Company, its Subsidiaries or, to the Knowledge of the Debtors, any Person
acting on the Company’s or any of its Subsidiaries’ behalf (including a contract manufacturer for the Products) has, with respect to any Product, (i) been subject to a Regulatory Authority shutdown, restriction, or import or export
prohibition or (ii) since January 5, 2018, received any FDA Form 483, or other written Regulatory Authority notice of inspectional observations, “warning letters,” “untitled letters” or requests or requirements to make
changes to the Products that if not complied with would reasonably be expected to have a material effect on the Company and its Subsidiaries, or similar correspondence or notice from any Regulatory Authority alleging or asserting noncompliance with
any applicable Law. 
 (f) None of the Company, its Subsidiaries or, to the Knowledge of the Debtors, any of their respective officers,
employees or agents, or, any clinical investigator acting for the Company or any of its Subsidiaries, has (i) made an untrue statement of a material fact or fraudulent statement to any Regulatory Authority, (ii) failed to disclose a
material fact required to be disclosed to any Regulatory Authority or (iii) committed an act, made a statement, or failed to make a statement, including with respect to any scientific data or information, that, at the time such disclosure was
made or failure to disclose occurred, would reasonably be expected to provide a basis for the FDA to invoke its policy respecting “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,” set forth in 56 Fed. Reg.
46191 (September 10, 1991), and any amendments thereto, or for any other Regulatory Authority to invoke any similar policy. None of the Company, its Subsidiaries or, to the Knowledge of the Debtors, any of their respective officers, employees
or agents, or, any clinical investigator acting for the Company or any of its Subsidiaries, is or has been convicted of any crime that has resulted in, or has engaged in any conduct that would reasonably be expected to result in, debarment from
participation in any program related to pharmaceutical products pursuant to 21 U.S.C. Section 335a (a) or (b), exclusion from participation in any federal healthcare program pursuant to 42 U.S.C.
Section 1320a-7, or disqualification as a clinical investigator under 21 C.F.R. § 312.70 or any similar Health Laws. 

(g) None of the Company, its Subsidiaries or, to the Knowledge of the Debtors, any of their respective officers, employees, or agents has,
(i) submitted any claim for payment to any government healthcare program in connection with any referrals related to the Products that violated in any material respect any applicable self-referral Law, including the Federal Ethics in Patient
Referrals Act, 42 U.S.C. §1395nn (known as the “Stark Law”), or any applicable state self-referral Law or (ii) submitted any claim for payment to any government healthcare program related to the Products in material violation of
any Laws relating to false claim or fraud, including the Federal False Claim Act, 31 U.S.C. § 3729, or any applicable state false claim or fraud Law. 

(h) All manufacturing operations relating to the Products conducted by or on behalf of the Company and its Subsidiaries have been and are
being conducted in material compliance with applicable provisions of current Good Manufacturing Practice requirements as set forth in 21 U.S.C. § 351(a)(2)(B), 21 C.F.R. Parts 210 and 211, and applicable guidance documents, as amended from
time to time. The Products have not been recalled, suspended, discontinued, or subject to any field notification, field correction, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of
the Products (a “Safety Notice”), either voluntarily by the Company or its Subsidiaries or at the request of the 

  
 43 

 
FDA or any other Regulatory Authority, nor has the Company or its Subsidiaries received any notice from the FDA or any other Regulatory Authority that it has commenced, or threatened to initiate,
any action to withdraw approval, place sales or marketing restrictions on or request the recall of, or seek a Safety Notice regarding the Products, or that it has commenced or threatened to initiate any action to enjoin or place restrictions on the
production of the Products. To the knowledge of the Debtors, no Product that is or has been manufactured, tested, distributed, held or marketed by or on behalf of the Company or any of its Subsidiaries has been adulterated or misbranded. In
addition, the Company and each of its Subsidiaries have filed all annual and periodic reports, amendments and safety reports required for any Product required to be made to any Regulatory Authority and, to the Knowledge of the Debtors, has submitted
to any Regulatory Authority all applicable patents for listing with the Regulatory Authority in the timeframe required by law and has taken all reasonable steps needed to request and maintain any statutory or regulatory exclusivity applicable to the
Products. 
 (i) The Company and its Subsidiaries have maintained records relating to the research, development, testing, manufacture,
handling, labeling, packaging, storage, supply, promotion, distribution, marketing, commercialization, import, export, and sale of the Products in material compliance with applicable Health Laws, and the Company and its Subsidiaries have submitted
to the FDA and other Regulatory Authorities in a timely manner all required notices and annual or other reports, including adverse experience reports and annual reports, related to the research, development, testing, manufacture, handling, labeling,
packaging, storage, supply, promotion, distribution, marketing, commercialization, import, export, and sale of the Products. 

Section 5.20 Taxes. 

(a) The Company and each of its Subsidiaries has prepared (or caused to be prepared) and timely filed (taking into account valid extensions of
time within which to file) all material Tax Returns required to be filed by any of them, and all such filed Tax Returns (taking into account all amendments thereto) are accurate and complete in all material respects. 

(b) All material Taxes owed by the Company and each of its Subsidiaries that are due and payable (whether or not shown as due on a Tax Return)
have been timely paid or, if not yet due and payable, adequately reserved against in accordance with GAAP. 
 (c) No deficiency for any
amount of material Taxes has been proposed or asserted in writing or assessed by any Taxing Authority against the Company or any of its Subsidiaries that remains unpaid or unresolved. 

(d) The Company and each of its Subsidiaries has not received written notice of any pending Causes of Action, examinations or proposed
adjustments in respect of any material amount of Taxes of the Company or any of its Subsidiaries. 
 (e) All material Taxes required to be
withheld or collected by the Company or any of its Subsidiaries have been withheld and collected and, to the extent required by applicable Law, timely paid to the appropriate Taxing Authority, and all IRS forms required with respect thereto have
been properly completed and timely filed. 

  
 44 

 (f) There are no material Encumbrances for Taxes on any of the assets of the Company or any
of its Subsidiaries, other than Encumbrances for Taxes or other governmental charges not yet due and payable or that are being contested in good faith by appropriate proceedings and are reflected on or specifically reserved against or otherwise
disclosed in any consolidated balance sheet included in the Financial Statements. 
 (g) Neither the Company nor any of its Subsidiaries has
been a “controlled corporation” or a “distributing corporation” in any distribution occurring during the two (2)-year period ending on the date of this Agreement that was purported or intended to be governed by Section 355
of the Code (or any similar provision of state, local or non-U.S. Law). 
 (h) No claim has been
received, or is expected by the Company to be received, with respect to the Company or any of its Subsidiaries from a Taxing Authority in a jurisdiction where such entity does not file Tax Returns that it is or may be subject to taxation by, or
required to file any Tax Return in, that jurisdiction which claim has not since been resolved. 
 (i) Neither the Company nor any of its
Subsidiaries has been a member of an affiliated group of corporations filing a consolidated federal income Tax Return (other than a group the common parent of which is the Company) or has had any liability for the Taxes of any person (other than the
Company or any of its Subsidiaries) under U.S. Treasury Regulation Section 1.1502-6 (or any similar provision of any state, local or non-U.S. Law), as a transferee
or successor. 
 (j) Neither the Company nor any of its Subsidiaries is a party to, or is bound by, or has any obligation under, any Tax
sharing Contract, Tax allocation agreement, Tax indemnity obligation or similar agreement or practice other than (A) Contracts solely among the Company and/or its Subsidiaries and (B) customary Tax indemnification provisions in Contracts
entered into in the ordinary course of business, the primary purpose of which does not relate to Taxes. 
 (k) Neither the Company nor any
of its Subsidiaries has currently in effect any waiver of any statute of limitations in respect of Taxes or any agreement to any extension of time with respect to the filing of a Tax Return or an assessment or deficiency for Taxes (other than
pursuant to extensions of time to file Tax Returns obtained in the ordinary course of business). 
 (l) Neither the Company nor any of its
Subsidiaries has participated in any “listed transaction” within the meaning of U.S. Treasury Regulations Section 1.6011-4(b). 

(m) The Company has made available to the Supporting Lenders accurate and complete copies of any private letter ruling requests, closing
agreements or gain recognition agreements with respect to Taxes of the Company or any of its Subsidiaries requested or executed in the past five (5) years. 

  
 45 

 Section 5.21 Insurance. The insurance policies maintained by the Company and its
Subsidiaries (the “Insurance Policies”) provide full and adequate coverage for all normal risks incident to the business of the Company and its Subsidiaries and their respective properties and assets, except for any such failures to
maintain such insurance policies that have not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Each of the Insurance Policies is in full force and effect and all premiums due with
respect to all Insurance Policies have been paid, except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 

Section 5.22 No Other Representations; No Reliance. 

(a) Notwithstanding the delivery or disclosure to the Supporting Lenders, any of their Affiliates or any of their respective Representatives
of any documentation or other information (including any financial projections or other supplemental data) or anything to the contrary in this Agreement, except for the representations and warranties expressly contained in this
Article V (in each case, as qualified by the Company Disclosure Letter), (i) neither the Company nor any other Person has made or is making, and each of the Company and its Affiliates expressly disclaims, any
representation or warranty of any kind or nature, whether express or implied, at Law or in equity, with respect to the accuracy or completeness of any information provided or made available to the Supporting Lenders by or on behalf of the Company in
connection with or related to this Agreement, the transactions contemplated hereby, or the completeness of any information provided in connection therewith and (ii) the Company hereby expressly disclaims any such other representations and
warranties. 
 (b) Except for the representations and warranties contained in Article VI, the Company acknowledges
that it (a) has had an opportunity to conduct any and all due diligence with respect to the Supporting Lenders and any of their respective Subsidiaries in connection with the transactions contemplated hereby, (b) has relied solely upon its
own independent review, investigation, and/or inspection of any documents in connection with the transactions contemplated hereby and (c) did not rely upon any written or oral statements, representations, promises, warranties, or guaranties
whatsoever, whether express, implied, by operation of Law, or otherwise regarding any Supporting Lender or any Subsidiaries or Affiliates thereof, or with respect to any other information provided or made available to the Company or any of its
Subsidiaries in connection with the transactions contemplated hereby, or the completeness of any information provided in connection therewith. 

ARTICLE VI 

REPRESENTATIONS AND WARRANTIES OF THE SUPPORTING LENDERS 

Each applicable Supporting Lender represents and warrants to the Company (as to itself only, severally and not jointly), as follows: 

Section 6.1 Qualification; Organization. Each Supporting Lender is a legal entity duly organized, validly existing and in good
standing (with respect to jurisdictions that recognize such concept) under the laws of its jurisdiction of organization and has all requisite corporate or similar power and authority to own, lease and operate its properties and assets and

  
 46 

 
to carry on its business as presently conducted, except where the failure to be so existing and in good standing or to have such power and authority would not, individually or in the aggregate,
materially impair or materially delay its ability to perform its obligations under this Agreement. Each Supporting Lender is qualified to do business and is in good standing (with respect to jurisdictions that recognize such concept) as a foreign
corporation or other entity in each jurisdiction where the ownership, leasing or operation of its assets or properties or conduct of its business requires such qualification, except where the failure to be so qualified or, where relevant, in good
standing, would not, individually or in the aggregate, materially impair or materially delay its ability to perform its obligations under this Agreement. 

Section 6.2 Corporate Authority. Each Supporting Lender has the requisite power and authority to execute and deliver (or to cause
one or more of its Affiliates to execute and deliver, as applicable) this Agreement and each other agreement, document or instrument contemplated hereby or thereby to which it is a party and, subject to the Company obtaining necessary Bankruptcy
Court approvals from and after the Petition Date, to carry out the Restructuring and to perform its obligations hereunder and thereunder. The execution and delivery of this Agreement and each other agreement, document or instrument contemplated
hereby or thereby to which it is a party and the consummation of the Transactions have been duly authorized by all requisite corporate or similar action on the part of each Supporting Lender. This Agreement and each other agreement, document or
instrument contemplated hereby or thereby to which it is a party has been duly and validly executed and delivered (subject, from and after the Petition Date, to the approval of the Bankruptcy Court). Subject to the Company obtaining necessary
Bankruptcy Court approvals from and after the Petition Date, this Agreement and each such other document have been duly and validly executed and delivered by each of the applicable Supporting Lenders and each of their applicable Affiliates, and,
assuming the due authorization, execution and delivery by the other Parties or their Affiliates, as applicable, constitute a legal, valid and binding agreement of each of the Supporting Lenders and their Affiliates, as applicable, enforceable
against such Person in accordance with its terms, subject to the Enforceability Limitations. 
 Section 6.3 Consents and
Approvals. Except as expressly provided in this Agreement or in the Bankruptcy Code and Section 5.4, no consent, waiver, approval, Order, permit or authorization (including those with respect to state licensing required
to operate the Business) of, or declaration, filing or registration with, or notification to, any Governmental Entity, including in connection or compliance with the HSR Act, is necessary or required on the part of (a) any Supporting Lender in
connection with the execution and delivery of this Agreement or any other agreement, document or instrument contemplated hereby to which such Supporting Lender is a party and (b) any applicable Affiliate of any Supporting Lender in connection
with the execution and delivery of any agreement, document or instrument contemplated hereby to which such Person is a party, or in connection with, the performance of such Person’s obligations hereunder and thereunder, or the consummation of
the Transactions (with or without notice or lapse of time, or both), except in each case of the foregoing clauses (a) and (b), for immaterial Consents. 

  
 47 

 Section 6.4 No Violations. The execution or delivery of this Agreement or any
agreement, document or instrument contemplated hereby or thereby by any Supporting Lender or any of its applicable Affiliates, the performance of such Person’s obligations hereunder and thereunder, and the consummation of the transactions
contemplated hereby or thereby, as applicable, do not and will not (a) conflict with or result in any violation or breach of any provisions of the certificate of incorporation, bylaws or other organizational documents of any such Person or
(b) conflict with or violate any Order or Law applicable to any Supporting Lender or its properties, rights or assets, except in the case of clause (b), for any conflicts or violations that (y) have not been and would not reasonably
be expected to be, individually or in the aggregate, material to the Business (taken as a whole) and (z) would not reasonably be expected to prevent or materially hinder or delay any of the Transactions or the transactions contemplated by any
of the Definitive Documents or affect the ability of the Supporting Lenders or their Affiliates, as applicable, to perform their obligations under this Agreement, the Restructuring Term Sheet or any of the Definitive Documents. 

Section 6.5 Brokers. Other than Houlihan Lokey Capital, Inc., the Supporting Lenders have not employed or engaged any investment
banker, broker or finder who is entitled to any brokerage, finder’s or other fee or any commission from the Supporting Lenders in connection with this Agreement, the Restructuring Term Sheet, the Definitive Documents, the transactions
contemplated by this Agreement or any other agreement, document or instrument contemplated hereby or thereby based upon arrangements made by or on behalf of the Supporting Lenders or any of their Affiliates. 

Section 6.6 Interested Stockholders. None of the Supporting Lenders nor any of their “affiliates” or
“associates” has been an “interested stockholder” of the Company at any time within three (3) years of the date of this Agreement, as those terms are used in Section 203 of the General Corporation Law of the State of
Delaware. 
 Section 6.7 Ownership of Claims. Each Supporting Lender represents and warrants to each of the other Parties that,
except as contemplated by the Interfund Transfers, as of the date such Party executes this Agreement or a Transferee Joinder, as applicable: (a) it either (i) is the sole legal and beneficial owner of the aggregate principal amount of
Claims set forth on its signature page, in each case, free and clear of any pledge, lien, security interest, charge, claim, proxy, voting restriction, right of first refusal or other limitation on disposition of any kind, in each case, that is
reasonably expected to adversely affect such Supporting Lender’s performance of its obligations contained in this Agreement or (ii) has full power and authority to vote the Claims (including Prepetition Credit Agreement Claims held through
participations or interests or pursuant to permissible transfers) set forth on its signature page; (b) it has full power and authority to vote on and consent to all matters concerning the Claims set forth on its signature page and to exchange,
assign, and transfer such Claims; (c) it is either (i) a qualified institutional buyer as defined in Rule 144A of the Securities Act or (ii) an institutional accredited investor as defined in Rule 501(a)(l), (2), (3) or
(7) under the Securities Act; (d) any securities acquired by a Supporting Lender in connection with the Restructuring described herein and in the Restructuring Term Sheet will be acquired for investment purposes and not with a view to
distribution in violation of the Securities Act; and (e) it has made no prior assignment, sale, participation, grant, conveyance or other Transfer of, and has not entered into any other agreement to assign, sell, participate, grant, convey or
otherwise Transfer, in whole or in part, any portion of its right, title, or interests in any Claims that is inconsistent with the representations and warranties of such Supporting Lender herein or would render such Supporting Lender otherwise
unable to comply with this Agreement and perform its obligations hereunder. 

  
 48 

 Section 6.8 No Other Representations; No Reliance. 

(a) Notwithstanding the delivery or disclosure to the Company, any of its Affiliates or any of their respective Representatives of any
documentation or other information (including any financial projections or other supplemental data) or anything to the contrary in this Agreement, except for the representations and warranties expressly contained in this
Article VI, (i) neither the Supporting Lenders nor any other Person has made or is making, and each of the Supporting Lenders and its Affiliates expressly disclaims, any representation or warranty of any kind or
nature, whether express or implied, at Law or in equity, with respect to the accuracy or completeness of any information provided or made available to the Company by or on behalf of the Supporting Lenders in connection with or related to this
Agreement, the transactions contemplated hereby, or the completeness of any information provided in connection therewith and (ii) the Supporting Lenders hereby expressly disclaim any such other representations and warranties. 

(b) Except for the representations and warranties contained in Article V, the Supporting Lenders acknowledge that
they (a) have had an opportunity to conduct any and all due diligence with respect to the Company and any of its respective Subsidiaries in connection with the transactions contemplated hereby, (b) have relied solely upon their own
independent review, investigation, and/or inspection of any documents in connection with the transactions contemplated hereby and (c) did not rely upon any written or oral statements, representations, promises, warranties, or guaranties
whatsoever, whether express, implied, by operation of Law, or otherwise regarding the Company or any Subsidiaries or Affiliates thereof, or with respect to any other information provided or made available to such Supporting Lender in connection with
the transactions contemplated hereby, or the completeness of any information provided in connection therewith. 
 ARTICLE VII 

COVENANTS 

Section 7.1 Interim Operations. 

(a) The Company covenants and agrees as to itself and its Subsidiaries that, during the Effective Period, except (i) as otherwise
expressly required or contemplated by this Agreement or the Restructuring Term Sheet, (ii) as required by applicable Law (including the Bankruptcy Code) or (iii) as consented to in writing by the Requisite Supporting Lenders (which consent
shall not be unreasonably withheld, conditioned or delayed), (x) the Business shall be conducted in the ordinary course of business consistent with past practice and in accordance with applicable Law and (y) the Company and its Subsidiaries
shall use their respective commercially reasonable efforts to preserve intact the Business and their relationship with customers, suppliers, distributors, wholesalers, retailers, employees and Governmental Entities. 

  
 49 

 (b) Without limiting the generality of, and in furtherance of, the foregoing, during the
Effective Period, except (x) as otherwise expressly required or contemplated by this Agreement or the Restructuring Term Sheet, (y) as required by applicable Law (including the Bankruptcy Code) or (z) as consented to in writing by the
Requisite Supporting Lenders (which consent shall not be unreasonably withheld, conditioned or delayed), the Company shall not, and shall not permit any of its Subsidiaries to, directly or indirectly: 

(i) amend the certificate of incorporation, bylaws or other organizational documents of the Company or its Subsidiaries; 

(ii) merge or consolidate the Company or any of its Subsidiaries with any other Person, or restructure, reorganize or
completely or partially liquidate the Company or any of its Subsidiaries or otherwise enter into any agreements providing for the sale of their respective material assets, operations or business; 

(iii) acquire assets outside of the ordinary course of business from any other Person; 

(iv) issue, sell, pledge, dispose of, grant, transfer, encumber, or authorize the issuance, sale, pledge, disposition, grant,
transfer or encumbrance of, any shares of capital stock or Equity Interests of the Company or any of its Subsidiaries (other than the issuance of shares by a wholly owned Subsidiary of the Company to the Company or another wholly owned Subsidiary),
or securities convertible or exchangeable into or exercisable for any shares of such capital stock or Equity Interests, or any options, warrants or other rights of any kind to acquire any of the foregoing; 

(v) incur, create or assume any Encumbrance (other than Permitted Encumbrances) on any properties or assets, tangible or
intangible, of the Company or any of its Subsidiaries; 
 (vi) (A) incur, assume or guarantee any Indebtedness or
capitalized lease obligations or issue any debt securities or (B) make any loans, advances, guarantees or capital contributions to, or investments in, any other Person; 

(vii) declare, set aside, make or pay any dividend or other distribution, payable in cash, stock, property or otherwise, with
respect to any of its capital stock or Equity Interests (except for dividends paid by any direct or indirect wholly owned Subsidiary to the Company or to any other direct or indirect wholly owned Subsidiary) or enter into any agreement with respect
to the voting of its capital stock or Equity Interests (other than this Agreement); 
 (viii) reclassify, split, combine,
subdivide or redeem, purchase or otherwise acquire, directly or indirectly, any of its capital stock or Equity Interests or securities convertible or exchangeable into or exercisable for any of the foregoing; 

(ix) except in accordance with the Budget (as defined in the Cash Collateral Orders), make or authorize any capital
expenditure; 

  
 50 

 (x) enter into any Contract that would have been a Material Contract had it
been entered into prior to this Agreement; 
 (xi) other than in the ordinary course of business, cancel or terminate (other
than, for the avoidance of doubt, any expiration in accordance with its terms), or modify or amend in any material respect, or waive any material rights under, any Material Contract; 

(xii) make any material changes with respect to material accounting policies or procedures, except as required by changes in
applicable Law or GAAP; 
 (xiii) settle or compromise any (A) Cause of Action (other than settlements involving only
unsecured claims with an allowed amount of less than one hundred thousand dollars ($100,000)), or (B) patent-related Cause of Action involving any of the Company Intellectual Property; 

(xiv) transfer, assign, sell, lease, grant (other than in the ordinary course of business) any license with respect to, or, to
the extent within the control of the Company or any of its Subsidiaries, abandon or permit to lapse, any material Intellectual Property; 

(xv) terminate or fail to renew any material Business Permit; 

(xvi) other than in the ordinary course of business, sell, pledge, dispose of, transfer or authorize the sale, pledge,
disposition or transfer of any assets or properties of the Company or its Subsidiaries; 
 (xvii) grant any material
licenses, sublicenses, covenants not to assert or similar rights with respect to any assets or properties, whether tangible or intangible, of the Company or its Subsidiaries; 

(xviii) fail to use commercially reasonable efforts to maintain the Insurance Policies or to renew or replace the Insurance
Policies following their termination; 
 (xix) except as required pursuant to the terms of any Debtor Plan in effect as of
the date of this Agreement or the Approved KEIP, (A) increase in any manner the compensation, consulting fees, incentive, bonus, retirement, welfare, fringe or other benefits, severance or termination pay of any employee or independent
contractor, (B) become a party to, establish, adopt, amend, commence participation in or terminate any Debtor Plan or any arrangement that would have been a Debtor Plan had it been entered into prior to this Agreement, (C) grant any new
awards, or amend or modify the terms of any outstanding awards, under any Debtor Plan, (D) take any action to accelerate the vesting or lapsing of restrictions or payment, or fund or in any other way secure the payment, of compensation or
benefits under any Debtor Plan, (E) change any actuarial or other assumptions used to calculate funding obligations with respect to any Debtor Plan that is required by applicable Law to be funded or change the manner in which

  
 51 

 
contributions to such plans are made or the basis on which such contributions are determined, except as may be required by GAAP, (F) forgive any loans or issue any loans (other than routine
travel advances issued in the ordinary course of business) to any employee, (G) hire any employee or engage any independent contractor (who is a natural person) other than the engagement of independent contractors to fill vacancies or staff
currently existing or contemplated projects to the extent not currently staffed or (H) terminate the employment of any officer other than for cause other than any officer who was provided with written notice of termination prior to the date of
this Agreement and who is listed on Section 7.1(b)(xix) of the Company Disclosure Letter; 
 (xx) become a party to,
establish, adopt, amend, commence participation in or terminate any collective bargaining agreement or other agreement with a labor union, works council or similar organization; 

(xxi) (A) change in any material respect any material method of accounting of the Company or its Subsidiaries for Tax
purposes; (B) enter into any agreement with any Taxing Authority (including a “closing agreement” under Code Section 7121) with respect to any material Tax or Tax Returns of the Company or its Subsidiaries; (C) surrender a
right of the Company or its Subsidiaries to a material Tax refund; (D) change an accounting period of the Company or its Subsidiaries with respect to any material Tax; (E) file an amended Tax Return; (F) change or revoke any material
election with respect to Taxes; (G) make any material election with respect to Taxes that is inconsistent with past practice; (H) file any Tax Return that is inconsistent with past practice; (I) consent to any extension or waiver of
the limitations period applicable to any material Tax claim or assessment (other than in the ordinary course of business); or (J) take any action (or fail to take any action) that would result in a loss of any material Tax losses, credits or
other attributes that may be used to reduce Tax liabilities (provided that, for the avoidance of doubt, the Company shall not be deemed to have violated the covenant in this clause (J) as the result of any action taken at the direction
of the Supporting Lenders in connection with the Interfund Transfers); 
 (xxii) revalue any assets or properties of the
Company or its Subsidiaries (including Inventory), except to the extent required by GAAP; or 
 (xxiii) agree, authorize or
commit, in writing or otherwise, to take any of the foregoing actions. 
 (c) The Supporting Lenders shall not knowingly take or permit any
of their Subsidiaries to take any action that is reasonably likely to prevent or materially impede the consummation of the Transactions. 

Section 7.2 Access and Information. Subject to applicable Law, the Company shall (and shall cause its Subsidiaries to) afford the
Supporting Lenders and the Supporting Lenders’ officers, directors, employees, agents, counsel, accountants, investment bankers, financing sources and other authorized Representatives reasonable access, during normal business hours and upon
reasonable advance notice, to all of the Company’s, its Subsidiaries’ and their applicable Affiliates’ properties, offices and Books and Records and, during such 

  
 52 

 
period, the Company shall (and shall cause its Subsidiaries to) furnish as promptly as practicable to the Supporting Lenders all information (financial or otherwise) the Supporting Lenders may
reasonably request concerning its Business; provided that no investigation pursuant to this Section 7.2 shall affect or be deemed to modify any representation or warranty made by the Company herein. Notwithstanding
the foregoing, the Company shall not be required by this Section 7.2 to provide the Supporting Lenders or their Representatives with access to or to disclose information (i) the disclosure of which would violate
applicable Law, (ii) that in the reasonable judgment of the Company would result in the disclosure of any Trade Secrets of third parties or violate any of its obligations with respect to confidentiality or (iii) to disclose any privileged
information of the Company or any of its Subsidiaries. 
 Section 7.3 Approvals and Consents; Cooperation; Notification. 

(a) Subject to the terms and conditions of this Agreement, the Company and the Supporting Lenders shall reasonably cooperate with each other
and use (and shall cause their respective Subsidiaries and Affiliates to use) their respective reasonable best efforts to take or cause to be taken all actions, and to do or cause to be done all things, reasonably necessary, proper or advisable on
their part under this Agreement and applicable Law to consummate the Transactions as soon as practicable after the date of this Agreement, including (i) unless otherwise agreed in writing by the Parties, obtaining as promptly as practicable all
necessary waiting period expirations or terminations, consents, clearances, waivers, licenses, Orders, registrations, approvals, permits, and authorizations necessary or advisable to be obtained from any third party and/or any Governmental Entity,
and (ii) preparing, filing and providing as promptly as practicable all documentation to effect all necessary notices, reports and other filings as may be necessary to obtain all such waiting period expirations or terminations, consents,
clearances, waivers, licenses, Orders, registrations, permits, approvals, permits or authorizations. Subject to applicable Laws relating to the exchange of information, the Supporting Lenders and the Company shall have the right to review in
advance, and, to the extent practicable, each will consult with the other on and consider in good faith the views of the other in connection with, all of the information relating to the Supporting Lenders or the Company or the Business, as the case
may be, and any of their respective Affiliates, that appears in any filing made with, or written materials submitted to, any third party and/or any Governmental Entity in connection with the Transactions. In exercising the rights specified in the
foregoing sentence, the Company and the Supporting Lenders shall act reasonably and as promptly as practicable. 
 (b) Each of the Parties
shall, in connection with and without limiting the efforts referenced in Section 7.3(a) to obtain any waiting period expirations or terminations, consents, clearances, waivers, licenses, Orders, registrations, approvals,
permits, and authorization for the Transactions under any Antitrust Law, (i) cooperate in all respects and consult with the other Parties in connection with any filing or submission with any Governmental Entity in connection with this
Section 7.3(b), including by allowing the other Parties to have a reasonable opportunity to review in advance and comment on drafts of filings or submissions and reasonably considering in good faith comments of the other
Parties and providing the other Parties with copies of filings and submissions, (ii) submit to customary background checks in connection therewith, (iii) respond promptly to any additional requests from Governmental Entities and
(iv) subject to applicable Laws and as required by any Governmental Entity, keep 

  
 53 

 
the other Parties reasonably apprised of the status of any waiting period expirations or terminations, consents, clearances, waivers, licenses, Orders, registrations, approvals, permits, and
authorization for the Transactions under any Antitrust Law to the extent relating to the completion of the Transactions and to the extent such party is aware of such information, including promptly furnishing the other with copies of notices or
other communications received by the Company or the Supporting Lenders or any of their respective Affiliates, as the case may be, from any Governmental Entity with respect to the foregoing clauses (i)-(iii); provided, however,
that materials required to be provided pursuant to the foregoing clauses (i)-(iv) may be redacted (A) to remove references concerning the valuation of any of the Parties or any of their respective Subsidiaries, (B) as necessary to
comply with contractual arrangements and (C) as necessary to address reasonable privilege or confidentiality concerns; provided further that any of the Parties may, as each deems advisable and necessary, reasonably
designate any competitively sensitive material provided to the other under this Section 7.3(b) as “Outside Counsel Only Material” and materials so designated shall only be provided to each party’s outside
counsel. 
 (c) Subject to applicable Laws and as required by any Governmental Entity, the Company and the Supporting Lenders each shall
keep the other reasonably apprised of the status of matters relating to completion of the Transactions to the extent such Party is aware of such information. 

(d) The Company shall cooperate with the Supporting Lenders and use (and shall cause its applicable Subsidiaries and Affiliates to use)
reasonable best efforts to take or cause to be taken all actions, and to do or cause to be done all things, reasonably necessary, proper or advisable on its part to complete the transfers among the Supporting Lenders described in Exhibit F
hereto (the “Interfund Transfers”). 
 (e) The Company shall use (and shall cause its applicable Subsidiaries and
Affiliates to use) reasonable best efforts to take or cause to be taken all actions, and to do or cause to be done all things, reasonably necessary, proper or advisable on its part to seek the assumption and approval of this Agreement and the
Debtors’ obligations hereunder at the Sale Hearing (as defined in the Bidding Procedures) if the Supporting Lenders are the Successful Bidder (as defined in the Bidding Procedures) at the Auction (as defined in the Bidding Procedures). 

(f) Notwithstanding the foregoing, nothing in this Agreement shall require the Supporting Lenders or their Affiliates to take or agree to take
any action with respect to its business or operations unless the effectiveness of such agreement or action is conditioned upon the completion of the Transactions. 

Section 7.4 Employee Matters. 

(a) For the twelve (12) month period commencing on the Effective Date, the Supporting Lenders shall permit the Company to honor, and
shall not cause the Company to reject, the severance agreements and the severance provisions of the employment agreement between the Company and any of its Subsidiaries and the applicable officer or employee of Company and any of its Subsidiaries,
in each case, as in effect as of the date of this Agreement and set forth on Section 7.4(a) of the Company Disclosure Letter, the Company’s and its Subsidiaries’ Severance Plan and the Incentive Compensation Plan. 

  
 54 

 (b) Prior to making any broad-based written or oral communications to officers and
employees of the Company or any of its Subsidiaries pertaining to compensation or benefit matters that are affected by the Transactions, the Company shall provide the Supporting Lenders with a copy of the intended communication, the Supporting
Lenders shall have no less than three (3) Business Days to review and comment on the communication, and the Company shall consider any such comments in good faith. 

(c) From and following the Effective Date, the Supporting Lenders shall procure that any employee benefit plans which the employees of the
Company and its Subsidiaries are entitled to participate in to take into account for purposes of eligibility, vesting and benefit accrual thereunder (other than any benefit accrual under any defined benefit pension plans), service by employees of
the Company and its Subsidiaries, to the same extent such service was credited under a comparable Debtor Plan (except to the extent it would result in a duplication of benefits). 

(d) Nothing contained in this Agreement is intended to: (i) be treated as an amendment of any particular Debtor Plan; (ii) prevent
the Company and any of its Subsidiaries, the Supporting Lenders or any of their Affiliates from amending or terminating any of their benefit plans or, after the Effective Date, any Debtor Plan in accordance with their terms; (iii) prevent the
Company and any of its Subsidiaries, the Supporting Lenders or any of their Affiliates, after the Effective Date, from terminating the employment of any employee of any of the Company and any of its Subsidiaries or their Subsidiaries; or
(iv) create any third-party beneficiary rights in any employee of the Company and any of its Subsidiaries or their Subsidiaries, any beneficiary or dependent thereof, or any collective bargaining representative thereof, with respect to the
compensation, terms and conditions of employment and/or benefits that may be provided to any such employee by the Company and any of its Subsidiaries, the Supporting Lenders or any of their Affiliates or under any benefit plan which any of the
Debtors, the Supporting Lenders or any of their Affiliates may maintain. 
 Section 7.5 Bidding Procedures. Notwithstanding any
other provision of this Agreement to the contrary, the Debtors and their respective Representatives shall have the right to initiate, solicit and encourage, whether publicly or otherwise, any Alternative Transaction, including by way of providing
access to non-public information pursuant to one or more customary confidentiality agreements, in each case, so long as such actions are in accordance with the Bidding Procedures and the Bidding Procedures
Order. The Parties acknowledge and agree that in the event that the Company enters into a definitive agreement with respect to an Alternative Transaction in accordance with the Bidding Procedures and the Bidding Procedures Order, then (i) all
obligations of the Parties with respect to the Transactions shall terminate, and (ii) nothing set forth in this Agreement shall restrict or prohibit the Debtors from taking any action that is permitted under the terms of such definitive
agreement. 

  
 55 

 ARTICLE VIII 

CONDITIONS PRECEDENT 

Section 8.1 Conditions to Obligation of the Company and the Supporting Lenders. The respective obligations of each Party to
consummate the Transactions shall be subject to the satisfaction at or prior to the Effective Date of the following conditions: 
 (a) No
Injunctions. There shall not be in effect any Order by a Governmental Entity of competent jurisdiction restraining, enjoining or having the effect of making the Transactions or the transactions contemplated by the Definitive Documents
illegal or otherwise prohibiting the consummation of the Transactions or the transactions contemplated by the Definitive Documents. No applicable Law shall have been enacted, entered, promulgated and remain in effect that prohibits or makes illegal
the consummation of the Transactions or the transactions contemplated by the Definitive Documents. 
 (b) Bankruptcy Court Orders.
The Bankruptcy Court shall not have entered an Order (i) dismissing the Chapter 11 Cases or converting the Chapter 11 Cases to a case under chapter 7 of the Bankruptcy Code, (ii) pursuant to Section 1104 of the Bankruptcy
Code appointing a trustee, receiver or an examiner to operate and manage any of the Company’s businesses or (iii) that is inconsistent with this Agreement, the Plan or the Confirmation Order in a manner adverse to the Supporting Lenders.

 (c) No Alternative Transaction. The Company shall not have entered into definitive documentation with respect to any Alternative
Transaction. 
 Section 8.2 Conditions to Obligation of the Company. The obligations of the Company to consummate the
Transactions shall be subject to the satisfaction or waiver (to the extent permitted by applicable Law) by the Company at or prior to the Effective Date of the following conditions: 

(a) Representations and Warranties. (i) The Lender Specified Representations, determined without regard to any qualification as to
materiality, shall be true and correct in all material respects at and as of the date of this Agreement and at and as of the Effective Date as though made at and as of the Effective Date, (ii) the representations and warranties of the
Supporting Lenders contained in Article VI (other than the Lender Specified Representations) shall be true and correct, determined without regard to any qualification as to materiality, at and as of the date of this
Agreement and at and as of the Effective Date as though made at and as of the Effective Date, except for such failures to be true and correct as would not, individually or in the aggregate, reasonably be expected to (x) prevent or materially
hinder or delay any of the Transactions or the transactions contemplated by any of the Definitive Documents or (y) affect the ability of the Supporting Lenders to perform their obligations under this Agreement or the Restructuring Term Sheet or
the Supporting Lenders or any of their Affiliates to perform their respective obligations under any of the Definitive Documents, in each case, in any material respect; provided, however, that in each of the foregoing clauses (i)
and (ii), any representations and warranties that are made as of a particular date or period shall be true and correct (in the manner set forth above), only as of such date or period. 

  
 56 

 (b) Covenants and Agreements. The covenants and agreements of the Supporting Lenders
to be performed at or prior to the Effective Date shall have been performed in all material respects in accordance with this Agreement. 

(c) Officer’s Certificate. Each of the Supporting Lenders shall have delivered to the Company a certificate duly
executed by an authorized officer of such Supporting Lender certifying to the effect that the conditions set forth in Section 8.2(a) and Section 8.2(b) have been satisfied. 

(d) Confirmation Order. The Bankruptcy Court shall have entered the Confirmation Order and if a timely appeal shall have been filed or
sought, (A) no stay of the Confirmation Order shall be in effect or (B) if such a stay shall have been granted, then (1) (x) the stay shall have been dissolved or lifted and (y) the appeal would not reasonably be expected to
prevent or materially impede the consummation of the Transactions or (2) a Final Order of the district court, circuit court, or other court having jurisdiction to hear such appeal shall have affirmed the Confirmation Order. 

Section 8.3 Conditions to Obligation of the Supporting Lenders. The obligations of the Supporting Lenders to consummate the
Transactions shall be subject to the satisfaction or waiver (to the extent permitted by applicable Law) by the Requisite Supporting Lenders at or prior to the Effective Date of the following conditions: 

(a) Representations and Warranties. (i) The Company Specified Representations, determined without regard to any qualification as
to materiality, shall be true and correct in all material respects at and as of the date of this Agreement and at and as of the Effective Date as though made at and as of the Effective Date, (ii) the representations and warranties of the
Company set forth in Article V (other than the Company Specified Representations and the representations and warranties set forth in Section 5.8(f)) shall be true and correct, determined without
regard to any qualification as to materiality or “Material Adverse Effect,” at and as of the date of this Agreement and at and as of the Effective Date as though made at and as of the Effective Date, except for such failures to be true and
correct as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect and (iii) the representations and warranties of the Company set forth in Section 5.8(f) shall be true and
correct at and as of the date of this Agreement and at and as of the Effective Date as though made at and as of the Effective Date; provided, however, that, in each case of the foregoing clauses (i) through (iii), any
representations and warranties that are made as of a particular date or period shall be true and correct (in the manner set forth above), only as of such date or period. 

(b) Covenants and Agreements. The covenants and agreements of the Company to be performed at or prior to the Effective Date shall have
been performed in all material respects in accordance with this Agreement. 
 (c) Officer’s Certificates. The
Company shall have delivered to the Supporting Lenders a certificate duly executed by an executive officer of the Company certifying to the effect that the conditions set forth in Section 8.3(a) and
Section 8.3(b) have been satisfied.  

  
 57 

 (d) Confirmation Order. The Confirmation Order shall be a Final Order. 

Section 8.4 Frustration of Conditions. No Party may rely on the failure of any condition set forth in
Section 8.1, Section 8.2 or Section 8.3, as the case may be, to be satisfied if such failure was caused by such Party’s breach of any provision of this Agreement.

 ARTICLE IX 

TERMINATION 

Section 9.1 Termination. 

(a) Mutual Termination. This Agreement and the obligations hereunder may be terminated by mutual written consent to terminate this
Agreement among the Company and the Requisite Supporting Lenders. 
 (b) Supporting Lender Termination. This Agreement and the
obligations hereunder shall automatically terminate three (3) Business Days (or such other notice period as specifically set forth below) following the delivery of written notice from the Supporting Lenders to the Company any time after and
during the continuance of any of the following events (each, a “Supporting Lender Termination Event”): 

(i) a breach of any of the covenants or agreements or any of the representations or warranties set forth in this Agreement on
the part of the Company which breach, either individually or in the aggregate with other breaches by the Company, would result in, if occurring or continuing on the Effective Date, the failure of the conditions set forth in
Section 8.3(a) or Section 8.3(b), as the case may be, and such breach is not curable or, if such breach is susceptible to cure, such breach remains uncured for a period of six (6) Business
Days after receipt of notice thereof (provided that the Supporting Lenders are not then in material breach of any of the covenants, agreements, representations or warranties set forth in this Agreement on the part of the Supporting Lenders);

 (ii) any Debtor shall pay or cause to be paid any amount outside of the ordinary course of business and inconsistent with
the Budget (as defined in the Cash Collateral Orders), subject to Permitted Variances (as defined in the Cash Collateral Orders), without the consent of the Requisite Supporting Lenders; 

(iii) the Bankruptcy Court shall have entered an unstayed Order dismissing one or more of the Chapter 11 Cases or
converting any of the Chapter 11 Cases to a case or cases under chapter 7 of the Bankruptcy Code; 
 (iv) an Order
denying confirmation of the Plan shall have been entered by the Bankruptcy Court or the Confirmation Order shall have been reversed, vacated or otherwise modified in a manner inconsistent with this Agreement or the Plan without the prior written
consent of the Requisite Supporting Lenders; 

  
 58 

 (v) any of the Debtors move to assume any executory Contracts or unexpired
Leases without the consent of the Requisite Supporting Lenders inconsistent with the Plan and such assumption is not remedied within three (3) Business Days following notice thereof to the Company by the Supporting Lenders; 

(vi) any court of competent jurisdiction or governmental authority, including any regulatory authority, shall have entered a
final, non-appealable judgment or order declaring the Restructuring, this Agreement, or any material portion hereof to be unenforceable or illegal or enjoining the consummation of a material portion of the
Restructuring and such judgment or order is not stayed, dismissed, vacated or modified within five (5) Business Days following notice thereof to the Company by the Supporting Lenders; provided, however, that in the case of a
stay, upon such judgment or order becoming unstayed and five (5) Business Days’ notice thereof to the Company by the Supporting Lenders, a Supporting Lender Termination Event shall be deemed to have occurred; 

(vii) the Company fails to comply with or achieve the Milestones set forth in Annex D to the
Restructuring Term Sheet; provided, however, the Company shall not have failed to comply with or achieve the Milestones set forth in Annex D to the extent that an extension of any such Milestones for up to
three (3) days is required to accommodate the Bankruptcy Court’s calendar; 
 (viii) the filing by the Company of
any motion or pleading with the Bankruptcy Court that is inconsistent with this Agreement and the Restructuring Term Sheet in any material respect and such motion is not withdrawn or appropriately modified within two (2) calendar days following
notice thereof to the Company by the Supporting Lenders; 
 (ix) the Bankruptcy Court grants relief that is inconsistent
with this Agreement or the Restructuring and such inconsistent relief is not dismissed, vacated or modified to be consistent with this Agreement and the Restructuring within five (5) Business Days following notice thereof to the Company by the
Supporting Lenders; 
 (x) any of the following shall have occurred: (a) the Company or any of its Affiliates shall
have filed any motion, application, adversary proceeding or cause of action (1) challenging the validity, enforceability, perfection or priority of, or seeking avoidance or subordination of any Claims (in any capacity) of the Prepetition
Lenders or the liens securing such Claims or (2) otherwise seeking to impose liability upon or enjoin the Prepetition Lenders (in any capacity); or (b) the Company or any affiliate of the Company shall have supported, encouraged or
solicited any other party to file any adversary proceeding or Cause of Action referred to in the immediately preceding clause (a) filed by a third party, or consents or does not object (without the consent of the Requisite Supporting
Lenders) to the standing of any such third party to bring such application, adversary proceeding or Cause of Action; 

  
 59 

 (xi) the Company (a) withdraws or revokes the Plan or files, propounds
or otherwise supports any chapter 11 plan other than the Plan, (b) cancel, terminate, abandon, cease or otherwise fail to complete the Auction (as defined in the Bidding Procedures) in accordance with the Bidding Procedures and the Bidding
Procedures Order other than in order to complete the Transactions, or (c) files or publicly proposes, announces, enters into or otherwise supports any (i) Alternative Transaction that is not in compliance with the Bidding Procedures and
the Bidding Procedures Order or (ii) amendment or modification to the Restructuring containing any terms that are inconsistent with the implementation of, and the terms set forth in, the Restructuring Term Sheet unless such amendment or
modification is otherwise consented to in accordance with Section 10.14; 
 (xii) on or after the
date of this Agreement the Company consummates any merger, consolidation, material disposition, material acquisition, material investment, dividend, incurrence of Indebtedness or other similar transaction outside the ordinary course of business that
is inconsistent with the restrictions set forth in Section 7.1(b), other than with the consent of the Requisite Supporting Lenders; 

(xiii) the Definitive Documents and any amendments, modifications or supplements thereto include terms that are inconsistent
in any material respect with this Agreement or the Restructuring Term Sheet and such inconsistency has not been corrected within three (3) Business Days after notice thereof has been given by the Supporting Lenders to the Company; 

(xiv) the Bankruptcy Court shall have entered an unstayed Order pursuant to Section 1104 of the Bankruptcy Code
appointing a trustee, receiver or an examiner to operate and manage any of the Company’s businesses; 
 (xv) the
Bankruptcy Court grants relief terminating, annulling, or modifying the automatic stay (as set forth in section 362 of the Bankruptcy Code) with regard to material assets of the Debtors without the consent of the Requisite Supporting Lenders; 

(xvi) the occurrence of any event, development, change or effect since the date of this Agreement that has had or would
reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect; 
 (xvii) the Company loses the
exclusive right to file and solicit acceptances of a chapter 11 plan; or 
 (xviii) the failure of the Company to pay
the fees and expenses of the Supporting Lenders in accordance with Section 10.13 of this Agreement, the Prepetition Credit Agreement, the Restructuring Term Sheet and the Cash Collateral Orders and such fees and expenses
are not paid within three (3) Business Days following notice thereof to the Company by the Supporting Lenders. 
 The Company hereby acknowledges and
agrees that the termination of this Agreement and the obligations hereunder as a result of a Supporting Lender Termination Event, and the delivery of any notice by the Supporting Lenders pursuant to any of the provisions of this
Section 9.1(b) shall not violate the automatic stay imposed in connection with the Chapter 11 Cases. 

  
 60 

 (c) Automatic Termination. This Agreement and the obligations hereunder shall
automatically and immediately terminate if, following the delivery of any notice by the Supporting Lenders pursuant to Section 9.1(b), the Company or any other
party-in-interest asserts that the termination of this Agreement or the delivery of such notice violates the automatic stay imposed in connection with the
Chapter 11 Cases. 
 (d) Company Termination. This Agreement and the obligations, hereunder may be terminated by the Company
upon three (3) Business Days advance written notice thereof to the Supporting Lenders (or such other notice period as specifically set forth below) upon the occurrence of any of the following events (each, a “Company Termination
Event”) unless (i) to the extent curable, such Company Termination Event has been cured by the applicable Supporting Lenders during such three (3) Business Day notice period (or such other applicable notice period as specifically
set forth below) or (ii) such Company Termination Event is waived in accordance with Section 10.14: 

(i) a breach of any of the covenants or agreements or any of the representations or warranties set forth in this Agreement on
the part of the Supporting Lenders which breach, either individually or in the aggregate with other breaches by the Supporting Lenders, would result in, if occurring or continuing on the Effective Date, the failure of the conditions set forth in
Section 8.2(a) or Section 8.2(b), as the case may be, and such breach is not curable or, if such breach is susceptible to cure, such breach remains uncured for a period of twenty (20) Business
Days after receipt of notice thereof (provided that the Company is not then in material breach of any of the covenants, agreements, representations or warranties set forth in this Agreement on the part of the Company); 

(ii) any court of competent jurisdiction or governmental authority, including any regulatory authority, shall have entered a
final, non-appealable judgment or order declaring the Restructuring, this Agreement, or any material portion hereof to be unenforceable or illegal or enjoining the consummation of a material portion of the
Restructuring and such judgment or order is not stayed, dismissed, vacated or modified within twenty-five (25) calendar days following notice thereof to the Supporting Lenders by the Company; provided, however, that in the
case of a stay, upon such judgment or order becoming unstayed and twenty-five (25) calendar days’ notice thereof to the Supporting Lenders by the Company, a Company Termination Event shall be deemed to have occurred; 

(iii) the Supporting Lenders fail to provide an extension of any of the Milestones as required to accommodate the Bankruptcy
Court’s calendar; 
 (iv) Deerfield fails, at any time during the Effective Period, to collectively hold or control
66.67% or more of the aggregate principal amount of the Prepetition Credit Agreement Claims; or 

  
 61 

 (v) the filing by the Supporting Lenders of any motion or pleading with the
Bankruptcy Court that is inconsistent in any material respect with this Agreement and the Restructuring Term Sheet. 
 Section 9.2
Termination Upon Effective Date or Outside Date. This Agreement shall terminate automatically without further required action or notice upon the sooner to occur of (a) Effective Date and (b) any Party’s written notice to the
other Parties of termination pursuant to this Section 9.2 on or after the Outside Date; provided, however, that the right to terminate this Agreement pursuant to this Section 9.2
shall not be available to any Party whose breach of any representation, warranty, covenant, or agreement set forth in this Agreement has been the cause of, or resulted in, the failure of the Plan to become effective on or before the Outside Date.

 Section 9.3 Effect of Termination. Upon termination of this Agreement, (a) this Agreement shall be of no further force
and effect and each Party shall be released from its commitments, undertakings and agreements under or related to this Agreement, and shall have all the rights and remedies that it would have had it not entered into this Agreement, and shall be
entitled to take all actions, whether with respect to the Restructuring or otherwise, that it would have been entitled to take had it not entered into this Agreement, including all rights and remedies available to it under applicable law;
provided, however, that the rights and obligations of the Parties under Section 10.13, if applicable, with respect to the payment of fees and expenses incurred up to such date of termination shall survive such
termination and all rights and remedies with respect to such claims shall not be prejudiced in any way; and (b) to the extent Bankruptcy Court permission shall be required for a Supporting Lender to change or withdraw (or cause to be changed or
withdrawn) its vote in favor of the Plan or any release, the Company shall support and not object to such change or withdrawal and shall use reasonable best efforts to modify or amend its Plan or other pleadings, as applicable, to permit such
Supporting Lender to change or withdraw (or cause to be changed or withdrawn) such vote or release. Nothing in this Section 9.3 shall relieve any Party from (i) liability for such Party’s breach of such
Party’s obligations hereunder or (ii) obligations under this Agreement that expressly survive termination of this Agreement pursuant to Section 10.6. 

ARTICLE X 
 GENERAL
PROVISIONS 
 Section 10.1 Agreement Effective Time. This Agreement shall become effective and binding upon each of the
Parties as of the date when counterpart signatures pages to this Agreement are executed and delivered by the Company and the Supporting Lenders. 

Section 10.2 No Solicitation. This Agreement is not and shall not be deemed to be a solicitation for votes for the acceptance of
the Plan (or any other chapter 11 plan) for the purposes of sections 1125 and 1126 of the Bankruptcy Code or otherwise or a solicitation to tender or exchange any securities. The acceptance of the Plan by the Supporting Lenders will not be
solicited until the Supporting Lenders have received the Disclosure Statement and related ballots. 

  
 62 

 Section 10.3 Purpose of Agreement. Each of the Parties acknowledges and agrees
that this Agreement is being executed in connection with negotiations concerning the Restructuring. 
 Section 10.4 Admissibility of
this Agreement. Each Party agrees that this Agreement, the Restructuring Term Sheet and all documents, agreements and negotiations relating thereto (including any prior drafts of any of the foregoing) shall not, pursuant to Rule 408 of the
Federal Rules of Evidence, any applicable state rules of evidence and any other applicable law, foreign or domestic, be admissible into evidence or constitute an admission or agreement in any proceeding involving a Party, other than the final
execution versions of this Agreement and the Exhibits thereto. 
 Section 10.5 Several, Not Joint Obligations. The agreements,
representations, and obligations of the Supporting Lenders under this Agreement are, in all respects, several and not joint. No prior history, pattern, or practice of sharing confidences among or between the Parties shall in any way affect or negate
this Agreement. 
 Section 10.6 Survival. Notwithstanding any termination of this Agreement pursuant to
Article IX, the agreements and obligations of the Parties in this Article X and Section 9.3 shall survive such termination and shall continue in full force and effect for
the benefit of the Parties in accordance with the terms hereof; provided, however, that any liability of a Party for failure to comply with the terms of this Agreement shall survive such termination. 

Section 10.7 Public Announcements. Unless otherwise required by applicable Law or by obligations of the Company or the Supporting
Lenders or their respective Affiliates pursuant to any listing agreement with or rules of any securities exchange or in order to enforce a party’s rights or remedies under this Agreement, the Company, on the one hand, and the Supporting
Lenders, on the other hand, shall consult with each other before issuing any other press release or otherwise making any public statement with respect to this Agreement, the Transactions or the activities and operations of the other and shall not
issue any such release or make any such statement without the prior written consent of the other (such consent not to be unreasonably withheld, conditioned or delayed). 

Section 10.8 Notices. All notices and other communications under this Agreement will be in writing and will be deemed given
(i) when delivered personally by hand, (ii) when sent by email (with written confirmation of transmission) or (iii) one Business Day following the day sent by overnight courier (with written confirmation of receipt), in each case, at
the following addresses and email addresses (or to such other address or email address as a Party may have specified by notice given to the other Party pursuant to this provision): 

  
 63 

	 	(a)	 if to the Supporting Lenders, to: 

Deerfield Management Company, L.P. 

780 Third Avenue, 38th Floor 

New York, New York 10017 

Email:         bsendrowski@deerfield.com 

epress@deerfield.com 

Attention:   Bryan Sendrowski 

Elliot Press 
 with copies (which
will not constitute notice) to: 
 Sullivan & Cromwell LLP 

125 Broad Street 
 New York, New
York 10004 
 Attention:    Brian E. Hamilton 

Ari B. Blaut 
 James L. Bromley

 Email:         hamiltonb@sullcrom.com 

blauta@sullcrom.com 

bromleyj@sullcrom.com 
 and 

 

	 	(b)	 if to the Company, to: 

Melinta Therapeutics, Inc. 
 44
Whippany Road, Suite 280 
 Morristown, New Jersey 07960 

Email:           Jsanfilippo@melinta.com 

Attention:     Jennifer Sanfilippo 

with copies (which shall not constitute notice) to: 

Skadden, Arps, Slate, Meagher & Flom LLP 

500 Boylston Street 
 Boston,
Massachusetts 02116 
 Facsimile:    (617) 573-4822 

Email:          graham.robinson@skadden.com 

christopher.novak@skadden.com 

Attention:    Graham Robinson 

Christopher E. Novak 

  
 64 

 and 

Skadden, Arps, Slate, Meagher & Flom LLP 

155 N. Wacker Drive 
 Chicago,
Illinois 60606 
 Facsimile:   (312) 407-0700 

Email:          ron.meisler@skadden.com 

christopher.dressel@skadden.com 

Attention:    Ron Meisler 

Christopher Dressel 
 and 

Skadden, Arps, Slate, Meagher & Flom LLP 

One Rodney Square 
 920 N. King
Street 
 Wilmington, Delaware 19801 

Facsimile:   (302) 651-3001 

Email:         faiz.ahmad@skadden.com 

richard.west@skadden.com 

Attention:    Faiz Ahmad 

Richard H. West 

Section 10.9 Descriptive Headings; Interpretative Provisions. The headings contained in this Agreement are for reference purposes
only and shall not affect in any way the meaning or interpretation of this Agreement. The words “hereof,” “herein” and “hereunder” and words of like import used in this Agreement shall refer to this Agreement as a whole
and not to any particular provision of this Agreement. References to Articles, Sections, Exhibits and Schedules are to Articles, Sections, Exhibits and Schedules of this Agreement unless otherwise specified. All Exhibits, Annexes and Schedules
annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. Any capitalized terms used in any Exhibit, Annex or Schedule but not otherwise defined therein, shall have the meaning
as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular. Where a word or phrase is defined herein, each of its other grammatical forms shall have a corresponding
meaning. Whenever the words “include,” “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation,” whether or not they are in fact followed by
those words or words of like import. Whenever the last day for the exercise of any right or the discharge of any duty under this Agreement falls on other than a Business Day, the party hereto having such right or duty shall have until the next
Business Day to exercise such right or discharge such duty. Unless otherwise indicated, the word “day” shall be interpreted as a calendar day. References to “dollars” or “$” mean United States dollars, unless otherwise
clearly indicated to the contrary. No summary of this Agreement prepared by or on behalf of any party hereto shall affect the meaning or interpretation of this Agreement. 

  
 65 

 Section 10.10 Representation by Counsel; No Strict Construction. Each Party
acknowledges that it has been represented by counsel (or had the opportunity to be so represented and waived its right to do so) in connection with this Agreement and the transactions contemplated by this Agreement. Accordingly, any rule of law or
any legal decision that would provide any Party with a defense to the enforcement of the terms of this Agreement against such Party based upon lack of legal counsel shall have no application and is expressly waived. This Agreement is the product of arm’s-length negotiations among the Parties and its provisions shall be interpreted in a neutral manner and one intended to effect the intent of the Parties. The Company, on the one hand, and the Supporting
Lenders, on the other hand, participated jointly in the negotiation and drafting of this Agreement, and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the Company
and the Supporting Lenders, and no presumption or burden of proof shall arise favoring or disfavoring any party hereto by virtue of the authorship of any provision of this Agreement. Without limitation as to the foregoing, no rule of strict
construction construing ambiguities against the draftsperson shall be applied against any person with respect to this Agreement. 

Section 10.11 Entire Agreement. Subject to the Restructuring Term Sheet and the Definitive Documents, this Agreement constitutes
the entire agreement between the Parties with respect to the subject matter hereof and supersedes any prior agreements and all other prior negotiations between and among the Company and the Supporting Lenders (and their respective advisors), oral or
written, between the Parties with respect thereto, to the maximum extent they relate in any way to the subject matter hereof; provided that the Parties acknowledge that any confidentiality agreements (if any) heretofore executed
between the Company and any Supporting Lender (and such Supporting Lender’s advisors) shall continue in full force and effect in accordance with and only to the extent of their respective terms. 

Section 10.12 Governing Law and Venue; Waiver of Jury Trial. 

(a) This Agreement, and all Causes of Action (whether in contract, tort or statute) that may be based upon, arise out of or relate to this
Agreement, or the negotiation, execution or performance of this Agreement (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Agreement or as an
inducement to enter into this Agreement), shall be governed by, and enforced in accordance with, the Laws of the State of New York, including its statutes of limitations, without giving effect to any borrowing statute or applicable principles of
conflicts of law to the extent that the application of the laws (including statutes of limitation) of another jurisdiction (whether of the State of New York or any other jurisdiction) would be required thereby. 

(b) By its execution and delivery of this Agreement, subject to the commencement of the Chapter 11 Cases, each Party hereby irrevocably
and unconditionally consents to submit to the exclusive jurisdiction of the Bankruptcy Court for the purpose of any Cause of Action, suit or proceeding arising out of or relating to this Agreement or any of the transactions contemplated hereby. At
any time prior to the filing of the Chapter 11 Cases, each of the Parties hereby irrevocably and unconditionally submits to the exclusive jurisdiction of the state or federal courts located within in the Borough of Manhattan, the City of New
York in the State of New York for purposes of any action, suit or proceeding arising out of or relating to this Agreement or any of the transactions contemplated hereby. Each party hereto hereby consents to service of process in the manner and at
the address set forth in Section 10.8. 

  
 66 

 (c) EACH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY
LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY ACTION BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY HEREBY ACKNOWLEDGES AND CERTIFIES (I) THAT NO REPRESENTATIVE,
AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION OR PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) IT UNDERSTANDS AND HAS CONSIDERED THE
IMPLICATIONS OF THIS WAIVER, (III) IT MAKES THIS WAIVER VOLUNTARILY AND (IV) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT, THE RESTRUCTURING TERM SHEET AND THE DEFINITIVE DOCUMENTS AND THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY
BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS SET FORTH IN THIS SECTION 10.12(C). 

Section 10.13 Transaction Expenses. The Debtors shall pay (a) one (1) Business Day prior to the Petition Date,
(b) subject to the Cash Collateral Orders, including the payment procedures set forth therein, on the Effective Date and (c) otherwise in accordance with the terms of any applicable fee letters and court orders during the pendency of the
Chapter 11 Cases, all accrued and unpaid fees, costs and expenses of the Supporting Lenders in connection with the Restructuring (provided that the amount paid pursuant to (a) above shall be agreed by the Debtors and the
Supporting Lenders and shall be less than the total amount of accrued and unpaid expenses owing to the Supporting Lenders as of such date) without the need to file any application with, or obtain any order from, the Bankruptcy Court, including,
without limitation, the fees, costs and expenses of (i) Sullivan & Cromwell LLP, (ii) Houlihan Lokey Capital, Inc., (iii) Landis Rath, (iv) any other professionals that may be retained by the Supporting Lenders in connection
with the Restructuring and (v) counsel for the Prepetition Agent. The Debtors shall also enter into ordinary and customary fee letters with the foregoing professionals and fund the retainers and other amounts required thereunder as a condition
precedent to the effectiveness of this Agreement. 
 Section 10.14 Amendments and Waivers. 

(a) Any amendment or modification of any term or provision of this Agreement or the Restructuring and any waiver of any term or provision of
this Agreement or of the Restructuring or of any default, misrepresentation, or breach of warranty or covenant hereunder shall not be valid unless the same shall be in writing and signed by the Company and the Requisite Supporting Lenders or
(ii) confirmed by email by both counsel to the Company and counsel to the Requisite Supporting Lenders representing that it is acting with the authority of the Company and the Requisite Supporting Lenders, respectively. 

  
 67 

 (b) In determining whether any consent or approval has been given or obtained by the
Requisite Supporting Lenders, the Requisite Supporting Lenders shall at all times be comprised of members who constituted the Requisite Supporting Lenders, and any loans held by any then-existing Supporting Lender, as applicable, that is in material
breach of its covenants, obligations or representations under this Agreement shall be excluded from such determination, and the loans held by such Supporting Lender, as applicable, shall be treated as if they were not outstanding. 

(c) Any waiver shall not be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant
hereunder or affect in any way any rights arising by virtue of any prior or subsequent default, misrepresentation, or breach of warranty or covenant. 

(d) The failure of any Party to exercise any right, power or remedy provided under this Agreement or otherwise available in respect hereof at
law or in equity, or to insist upon compliance by any other Party with its obligations hereunder shall not constitute a waiver by such Party of its right to exercise any such or other right, power or remedy or to demand such compliance. 

(e) Notwithstanding anything to the contrary in this Section 10.14, no amendment, modification or waiver of any term
or provision of this Agreement or the Restructuring shall be effective with respect to any Supporting Lender without such Supporting Lender’s prior written consent to the extent such amendment, modification or waiver materially affects such
Supporting Lender in a manner that is disproportionately adverse to such Supporting Lender in relation to the other Supporting Lenders. 

(f) All rights, powers, and remedies provided under this Agreement or otherwise available in respect hereof at law or in equity shall be
cumulative and not alternative, and the exercise of any right, power, or remedy thereof by any Party shall not preclude the simultaneous or later exercise of any other such right, power, or remedy by such Party. 

Section 10.15 Parties, Succession and Assignment. This Agreement shall be binding upon, and inure to the benefit of, the
Parties and their respective successors, assigns, heirs, executors, estates (including the Estates), administrators and representatives. No rights or obligations of any Party under this Agreement may be assigned or transferred to any other person or
entity except as otherwise expressly provided herein. Nothing in this Agreement, express or implied, shall give to any person or entity, other than the Parties (and those permitted assigns under Section 3.3), any benefit or
any legal or equitable right, remedy or claim under this Agreement; provided, however, that a Supporting Lender may assign some or all of its rights or delegate some or all of its obligations hereunder to one or more Affiliates without
any other Party’s consent. Upon any such permitted assignment, the references in this Agreement to the applicable Party will also apply to any such assignee unless the context otherwise requires. 

Section 10.16 No Waiver of Participation and Reservation of Right. Except as expressly provided in this Agreement or the Plan,
nothing herein is intended to, nor does, in any manner waive, limit, impair, or restrict any right of any Party or the ability of each of the Parties to protect and preserve its rights, remedies and interests, including Claims against and interests
in the Company. If the Restructuring is not consummated, or following the occurrence of a Supporting Lender Termination Event, a Company Termination Event, an event triggering automatic termination pursuant to
Section 9.1(c), or the termination of this Agreement, nothing herein shall be construed as a waiver by any Party of any or all of such Party’s rights, and the Parties expressly reserve any and all of their respective
rights. 

  
 68 

 Section 10.17 No Third-Party Beneficiaries. This Agreement shall not confer any
rights or remedies upon any person other than the Parties and their respective successors and permitted assigns, except as expressly set forth in this Agreement. 

Section 10.18 Counterparts; Effectiveness. This Agreement may be executed in one or more counterparts, each of which will be
deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile or by electronic mail in portable
document format (.pdf), which shall be deemed to be an original for the purposes of this Section 10.18. 

Section 10.19 Severability. The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of
any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other authority of competent jurisdiction to be
invalid, void or unenforceable, or the application of such provision, covenant or restriction to any Person or any circumstance, is held by a court of competent jurisdiction or other authority to be invalid, void or unenforceable, (a) a
suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the remainder of this Agreement and the
application of such provision, covenant or restriction to other Persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of such
provision, or the application of such provision, in any other jurisdiction and the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or
invalidated. 
 Section 10.20 Specific Performance. Each Party hereto recognizes and acknowledges that a breach by it of any
covenants or agreements contained in this Agreement would cause the other Parties to sustain damages for which such Parties would not have an adequate remedy at law for money damages, and therefore each Party hereto agrees that in the sole event of
any breach, the other Parties shall be entitled to the remedy of specific performance and injunctive or other equitable relief (including attorney’s fees and costs) to enforce such covenants and agreements, in addition to any other remedy to
which such non-breaching Party may be entitled, at law or in equity, without the necessity of proving the inadequacy of money damages as a remedy, including an order of the Bankruptcy Court requiring any Party
to comply promptly with any of its obligations hereunder. 
 Section 10.21 Conflicts. In the event the terms and conditions set
forth in the Restructuring Term Sheet and in this Agreement are inconsistent, the Restructuring Term Sheet shall control. In the event of any conflict among the terms and provisions of the Plan, this Agreement and the Restructuring Term Sheet, the
terms and provisions of the Plan shall control. In the event of any conflict among the terms and provisions of the Confirmation Order, the Plan, 

  
 69 

 
this Agreement and the Restructuring Term Sheet, the terms of the Confirmation Order shall control. Notwithstanding the foregoing, nothing contained in this
Section 10.21 shall affect, in any way, the requirements that the Plan and the Confirmation Order be in all material respects materially consistent with this Agreement and the Restructuring Term Sheet and the requirements
set forth herein for the amendment of this Agreement. 
 [Signature Page Follows] 

  
 70 

 IN WITNESS WHEREOF, the Company and the Supporting Lenders have caused this Agreement to be
executed on their behalf as of the date first written above. 
  

			
	MELINTA THERAPEUTICS, INC.
		
	By:	 	 /s/ Jennifer A. Sanfilippo

		 	Name: Jennifer A. Sanfilippo
		 	Title:   Interim Chief Executive Officer

 
							
	SUPPORTING LENDERS:
	
	DEERFIELD PRIVATE DESIGN FUND III, L.P.
	
	By: J.E. Flynn Capital III, LLC, its General Partner
		
	By:	 	 /s/ David J. Clark

		 	Name: David J. Clark
		 	Title: Authorized Signatory
	
	DEERFIELD PRIVATE DESIGN FUND IV, L.P.
	
	By: Deerfield Mgmt IV, L.P., its General Partner
		
	By:	 	 /s/ David J. Clark

		 	Name: David J. Clark
		 	Title: Authorized SignatoryEX-10.1

 Exhibit 10.1 

MIRUM PHARMACEUTICALS, INC. 

May 15, 2019 
 Mike Grey 

[...***...] 
  

	Re:	 Amended and Restated Employment Terms 

Dear Mike: 
 MIRUM
PHARMACEUTICALS, INC. (the “Company”) is pleased to confirm your appointment as Executive Chairman, pursuant to the following terms of this Amended and Restated Offer Letter (this
“Offer Letter”), effective as of March 12, 2019 (the “Effective Date”). This Offer Letter amends and restates the Offer Letter, dated December 1, 2018, by and between the Company and you (the
“Prior Letter”). 
 You will be responsible for working closely with the Company’s Board of Directors (the
“Board”) and the executive team of the Company to further the goals and objectives of the Company, consistent with the usual and customary duties of an Executive Chairman. You will work at the Company’s U.S. headquarters
in Foster City. Of course, the Company may change your position, duties, and work location from time to time in its discretion. 
 As of the Effective Date,
your base salary will continue to be $300,000 on an annualized basis, less payroll deductions and withholdings, paid on the Company’s normal payroll schedule. You will also be eligible to earn an annual performance bonus, with a target bonus of
40% of your annual base salary, based on the attainment of individual and/or Company objectives. The attainment of such objectives, and the actual amount (if any) of such bonus, will be determined by the Company in its sole discretion, and any such
bonus will not be deemed earned unless you are an employee of the Company in good standing on the dates the bonus is determined and paid. 
 During your
employment, you will be eligible to participate in the standard benefits plans offered to similarly situated employees by the Company from time to time, subject to plan terms and generally applicable Company policies. A full description of these
benefits is available upon request. Exempt employees may take a reasonable amount of time off with pay, as permitted by their duties and responsibilities, and as approved in advance by their supervisor. Exempt employees do not accrue vacation, and
there is no set guideline as to how much vacation each employee will be permitted to take. Supervisors will approve paid vacation requests based on the employee’s progress on work goals or milestones, status of projects, fairness to the working
team, and productivity and efficiency of the employee. Since vacation is not allotted or accrued, “unused” vacation time will not be carried over from one year to the next nor paid out upon termination. The Company may change compensation
and benefits from time to time in its discretion. 
 Subject to approval by the Board, the Company anticipates granting you an option to purchase 2,100,000
shares of the Company’s common stock at the fair market value as determined by the Board as of the date of grant (the “Option”). The anticipated Option will be governed by the terms and conditions of the Company’s
2018 Equity Incentive Plan (the “Plan”) and your grant agreement, and will include a four year vesting schedule, under which 25% of your Option will vest 12 months after the vesting commencement date, and 1/48th of the total
shares will vest at the end of each month thereafter, until either the Option is fully vested or your continuous service (as defined in the Plan) terminates, whichever occurs first. For the avoidance of doubt, the Option shall be in addition to the
option grant contemplated by the Prior Letter. 

  
 Page 1 

 As a Company employee, you will be expected to abide by Company rules and policies. As a condition of
employment, you must continue to comply with the Employee Confidential Information and Inventions Assignment Agreement previously executed by you which prohibits unauthorized use or disclosure of the Company’s proprietary information, among
other obligations. 
 In your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets, of
any former employer or other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information which is generally known and used by persons with training and experience comparable to your own, which
is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto Company premises any unpublished documents or property belonging to any
former employer or other person to whom you have an obligation of confidentiality. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities on behalf of the Company. 

Normal business hours are from 9:00 a.m. to 5:00 p.m., Monday through Friday. As an exempt salaried employee, you will be expected to work additional hours as
required by the nature of your work assignments. 
 Your employment with the Company will be “at-will.”
You may terminate your employment with the Company at any time and for any reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time, with or without cause or advance notice. Your employment at-will status can only be modified in a written agreement signed by you and by an officer of the Company. The foregoing does not modify any of your rights under the Company’s Severance Benefit Plan. 

To ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company agree that
any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Offer Letter, your employment with the
Company, or the termination of your employment, shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS or its successor, under JAMS’ then applicable rules and procedures for
employment disputes (available upon request and also currently available at http://www.jamsadr.com/rules-employment-arbitration/). You acknowledge that by
agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. You will have the right to be represented by legal counsel at any
arbitration proceeding. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written statement signed
by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The arbitrator shall be
authorized to award all relief that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the administrative fees that you would be required to pay if the dispute were decided in
a court of law. Nothing in this Offer Letter is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. 

  
 Page 2 

 This Offer Letter, together with your Employee Confidential Information and Inventions Assignment Agreement,
forms the complete and exclusive statement of your employment agreement with the Company. It supersedes any other agreements or promises made to you by anyone, whether oral or written. Changes in your employment terms, other than those changes
expressly reserved to the Company’s discretion in this Offer Letter, require a written modification signed by an officer of the Company. If any provision of this Offer Letter is determined to be invalid or unenforceable, in whole or in part,
this determination shall not affect any other provision of this Offer Letter and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable
law. This Offer Letter may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission
method and shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 
 Please sign and date this Offer Letter to
confirm your continued employment with the Company under the terms described above. 
 Sincerely, 

 

					
	 /s/ Chris Peetz
	 		 	
	Chris Peetz, President and Chief Executive Officer	 		 	
			
	Understood and Accepted:	 		 	
			
	 /s/ Michael Grey
	 		 	 5/23/2019

	Michael Grey	 		 	Date
	[...***...]@mirumpharma.com	 		 	

  
 Page 3 

 MIRUM PHARMACEUTICALS, INC. 

December 24, 2019 
 Mike Grey 

[...***...] 
 Re: Termination of Employment and
Transition to Chairman of the Board 
 Dear Mike: 

This letter (this “Letter”) is to confirm our mutual agreement that as part of a planned management transition, your
employment as Executive Chairman of Mirum Pharmaceuticals, Inc. (the “Company”) will terminate effective as of December 31, 2019 (the “Separation Date”), and effective as of January 1, 2020,
you will transition into the role of Chairman of the Board of Directors of the Company (the “Board”). 

Notwithstanding your termination of employment on the Separation Date, you will still be eligible to achieve your 2019 annual performance
bonus as described in the Amended and Restated Offer Letter, dated May 15, 2019, by and between the Company and you (the “Offer Letter”), as determined by the Company in its sole discretion. In addition, the transition
of your status from employee to Chairman of the Board will be deemed “Continuous Service” for purposes of the continued vesting of your outstanding stock options, and will not be considered a termination giving rise to the Company’s
repurchase option with respect to the outstanding shares of common stock beneficially owned by you that remain subject to vesting. 
 As of
the Separation Date, your participation in the Company’s Severance Benefit Plan (the “Severance Plan”), will cease. For clarity, the termination of your employment pursuant to this Letter does not entitle you to any
benefits under the Severance Plan. 
 In connection with your appointment as Chairman of the Board and subject to approval by the Board, the
Company anticipates granting you an option to purchase 100,000 shares of the Company’s common stock at the fair market value as determined by the Board as of the date of grant (the “Option”). The anticipated Option will
be governed by the terms and conditions of the Company’s 2019 Equity Incentive Plan (the “Equity Incentive Plan”) and your grant agreement, and will include a four year vesting schedule, under which 1/48th of the shares subject to your Option will vest at the end of each month after the vesting commencement date, until either the Option is fully vested or your continuous service (as defined in the
Equity Incentive Plan) terminates, whichever occurs first. 
 Additionally, in connection with your service as Chairman of the Board, you
will receive an annual cash retainer of $65,000, in addition to the $35,000 annual cash retainer for all directors under the Company’s non-employee director compensation policy. 

This Letter shall be deemed an amendment to the Offer Letter. 

Sincerely, 
 /s/ Chris Peetz 

					
	  
 Chris Peetz, President and Chief
Executive Officer
	 		 	    

 Understood and Accepted: 
  

					
	 /s/ Michael Grey

Michael Grey
	 		 	 12/24/2019

Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]